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ABSTRACT  
 
Background:  The European Association for the Study of the Liver (EASL) Guidelines for 
Hereditary Haemochromatosis (HH) refer specifically to symptomatic Homozygous C282Y patients 
and provide an algorithm for treating such patients who are predisposed to iron overloading.  The 
British Society of Echocardiography does not make provisions for HH patients per se.  Cardiac 
failure is a known complication of severe iron overload although it is atypical. 
 
Aim:  To retrospectively investigate if an echocardiogram (echo) was warranted in the HH 
population at Louth County Hospital (LCH) Venesection Clinic based on the current guidelines. 
 
Methods:  A cohort of 833 HH patients was reviewed with respect to: Hyperferritinemia (HFE) 
genotype, echo results, serum ferritin levels, transferrin saturations, patient gender, age at HH 
diagnosis and co-morbidities. 
 
Results:  From the cohort investigated, 553 of 833 patients (66 percent) had echoes performed.  
When reviewing all echo results for these patients (553), 87 percent (480) recorded normal echoes.  
Consolidating all echoes performed where Serum Ferritin Level data was present (548) and then 
targeting patients with no co-morbidities only (345), the LCH Venesection Clinic data analysis 
demonstrates that 92 percent of this cohort’s echoes (319) show normal results.     
 
Conclusion:  The results proved the thesis hypothesis was valid and a recommendation that the 
number of patients receiving echoes for Hereditary Haemochromatosis should be reviewed and local 
policy changed to reflect a lower frequency rate for echoes required, thereby reducing the backlog 
waiting list.    
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Chapter 1 :  Introduction to an Echocardiography Audit 
on Patients with Hereditary Haemochromatosis 
1.1 Introduction 
The purpose of this study was to review the exponential increase in the number of 
echocardiograms (echoes) being requested for Hereditary Haemochromatosis (HH) patients 
from the Louth County Hospital (LCH) Venesection Clinic.   
The demonstrated data trend of increased requests from the LCH venesection clinic is shown 
in Fig. 1.1.  Taking 2009 as a baseline, 2014 showed a 1354% increase in venesection echoes 
completed.  When related to the known capacity of the echocardiography department this 
increase in requests was creating a direct amplification in patient waiting lists.  Most 
importantly, as requests are dealt with on a first come first served basis, the relative 
importance of patient treatment needs was not being taken into account.  This could 
potentially lead to delay of urgent echoes critical to a patient treatment outcome.  
Fig. 1.1 Trendline of Louth County Hospital Venesection Clinic Echoes Completed 
Annually 
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The objective of this study was to retrospectively investigate if an echo was warranted in the 
HH population of the LCH venesection clinic.  Then, following from the conclusions of this 
study, recommend to the Gastroenterology department whether the guiding principles of LCH 
should be retained or revisited if contrary to the conclusions.  
As a brief introduction to the clinical aspects of this thesis, the three central terms are defined 
and explained in this section. 
An echocardiogram, as defined by the American Heart Association is a test that uses high 
frequency sound waves (ultrasound) to make pictures of the heart.   
According to Pietrangelo’s definition (Pietrangelo; 2015), Haemochromatosis is:  
“any genetic or acquired defect that directly or indirectly persistently causes 
unchecked transfer of iron into the blood (from the intestine and storage/recycling 
sites, such as spleen and liver) and toxicity in parenchymatous organs, can cause the 
clinical syndrome called hemochromatosis.”   
Furthermore, “Hemochromatosis may be divided into primary (or genetic) hemochromatosis 
and secondary hemochromatosis” (Zakim and Boyers; 2011).  Primary or classical HH is 
caused by defective genes inherited from the parent(s).  It is associated with two mutations in 
the hyperferritinemia (HFE) gene namely; C282Y and H63D (see Fig. 1.2) named after the 
chromosome defect positions.  This will be discussed further in chapter three.  For the 
purpose of this audit, only primary HH is being reviewed. 
“Hereditary hemochromatosis is an autosomal recessive disorder of iron metabolism. 
‘Autosomal’ means that the gene is on one of the first 22 pairs of chromosomes, and 
not on the X or Y chromosome (HFE is located on chromosome 6). Therefore, males 
and females are equally affected by the disease.  "Recessive" means that two copies of 
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the defective gene, one inherited from each parent, are necessary to have the 
condition.  That means that you usually have to have two copies of the defective HFE 
gene before you are at risk of developing hereditary hemochromatosis.” 
(www.hemochromatosisdna.com/dna-testing/about-the-dna-test)
 
Fig. 1.2 Haemochromatosis a recessive, inherited disorder. 
Source: www.haemochromatosis-ir.com/how_is_haemochromatosis_inherited.html 
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Venesection (or phlebotomy) is the act of drawing or removing blood through a cut (incision) 
or puncture for the purpose of analysis, blood donations or treatment of blood disorders (Assi 
& Baz; 2014). 
 
1.2 Thesis Structure 
Chapter one introduces the thesis structure.  This includes an introduction to the problem 
statement, purpose and objectives of the study, the author’s viewpoint as an 
Echocardiographer (a specially trained Cardiac Physiologist) and the reasons why this study 
was undertaken.   
 
An outline of each chapter’s focus, its interaction with subsequent chapters and its 
relationship to the study is justified throughout the Introduction section.  In addition, the 
study methodology is described and a brief summary of the conclusions is presented.  Finally, 
potential future use for the study and the data is proposed. 
 
Chapter two reviews the background of the study examining the guidelines put forward by 
the British Society of Echocardiography (BSE), the American College of Cardiology (ACC) 
and the European Association for the Study of the Liver (EASL). 
 
Chapter three reviews HH.  This is central to the study as the cohort of patient data analysed 
stem from the Haemochromatosis venesection clinic in LCH.  Comments on HH definitions, 
its history and genetics are reviewed.  Additionally, the prevalence and penetrance of HH in 
Europe and Ireland is assessed.   
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Chapter four focuses on a review of blood and its constituent parts in relation to HH.  It is 
reviewed at human body system and cellular levels.  Particular attention is paid to iron 
metabolism and iron homeostasis, Hepcidin (systemic iron regulatory hormone), the affects 
of Iron accumulation/overload and in particular cardiac manifestations and its relationship to 
HH. 
 
Chapter five examines the human heart, its physiology and functions.  The mechanisms of 
iron overload in the heart are examined and evidence of cardiological symptoms is 
considered.  Next, transthoracic echocardiography (also known as diagnostic ultrasound, an 
echocardiogram, or an echo) is reviewed in general followed by particular assessment criteria 
for patients with HH.  The American Heart Association (2015) explains an echocardiogram 
as a test that uses high frequency sound waves (ultrasound) to make moving pictures of your 
heart. Finally, systolic and diastolic dysfunction are examined and the usefulness of echo 
findings for HH treatment is reassessed. 
 
Chapter six is a review of the research process and methodology the author employed during 
this study and the key data is given in evidence to support the conclusions.   
 
Chapter seven is a presentation of this project’s audit data and analysis of the data. 
Fundamental measurements and indicators discussed in chapters three, four and five are 
reviewed and presented with figures and observations from the LCH venesection patient 
record data audit.   
 
   
 6 
Chapter eight discusses the experiences, challenges and beneficial outcomes the study has 
engendered on the trend of HH Echo requests from the venesection clinic. It also reviews 
how this research may contribute to future research and learning in this field. 
 
Chapter nine closes this study thesis.  In this final chapter, the conclusions and three 
recommendations for the Gastroenterology department are presented for review. 
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Chapter 2 : Background to the Need for a Primary 
Research Audit on Venesection Echocardiography 
Services   
 
2. 1 Introduction 
In order to have a meaningful and unbiased review of the objective, an assessment of 
guidelines from the governing bodies of the BSE, EASL and ACC was completed.   
The BSE guidelines are based on “literature searching conducted in Medline, EMBASE, 
Cochrane library for English-language meta-analyses and systematic reviews from 1990 – 
2006” (Appendix 1) and provide recommendations for performing echoes based on clinical 
studies.  The BSE does not make such provisions for HH patients per se.  The indications do 
not mention haemochromatosis as an indication for Echocardiography.  This does not 
preclude a physician ordering an echo should they discern that there is a clinical basis for the 
test.  Intrinsically, HH alone with no other co-morbidities to support echo is not a BSE 
indication for echocardiography (see appendix 1 for further detail).   
Contrary to the BSE recommendations, the EASL Guidelines for HH refer specifically to 
symptomatic homozygous C282Y patients only and provide an algorithm for treating such 
patients who are predisposed to iron overloading see Fig. 2.1.  The algorithm addresses those 
patients with the potent version of HH (homozygous C282Y patients) only, but does not 
address those patients who are homozygous H63D; compound heterozygous C282Y/H63D; 
C282Y carriers nor H63D carriers.  EASL Guidelines also note that glycated hemoglobin 
(HbA1c), serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
should be reviewed and if symptomatic, then echocardiography should be performed.  AST, 
HbA1c and ALT are biochemical blood markers that indicate liver damage or hepatotoxicity. 
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The ACC also provides an algorithm for assessing patients who are ‘at risk’ of Iron Overload 
Cardiomyopathy (IOC), suggesting that an echo with full diastolic function assessment 
should be undertaken, see Fig. 2.2.  The relationship of IOC with HH has been well 
considered in literature reviews (Schreiber, 1957).  A fundamental point here is those ‘at risk’ 
of IOC need echocardiography.  Conversely, it could be said that those not ‘at risk’ do not 
require echocardiography.  This is a salient point this thesis will review.           
 
Fig. 2.1 EASL Proposed algorithm for the diagnostic management of patients with 
C282Y homozygosity 
Source: (www.jhep-elsevier)  
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Liu and Olivieri (1994) define IOC as “the presence of systolic or diastolic cardiac 
dysfunction secondary to increased deposition of iron in the heart independent of other 
concomitant processes.”   
 
Fig. 2.2 Proposed clinical pathway to evaluate patients with idiopathic cardiomyopathy 
or those at risk for iron overload 
 Source: Adapted from PubMed Central, J Am Coll Cardiol. 2010 Sep 21; 56(13) 1001–
1012. doi   10.1016_j. jacc.2010.03.083 
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These apparent contradictions between the clinical discipline guidelines regarding whether an 
Echo should or should not be performed on the venesection clinic patient cohort is a 
paramount question related to this thesis.  The cost/benefit analysis of pursuing one path or 
the other from a positive clinical patient outcome, departmental capacity management and 
monetary viewpoint will be presented in the Discussion Chapter 8.       
 
2.2  Author and Echocardiography Background 
The author has more than 20 years of clinical cardiology experience in both the public and 
private sectors, is an accredited member of the BSE and has been employed as an 
Echocardiographer in LCH during the past ten years including the period of this study.   
 
Echocardiography can be described as an ultrasound technique used to image the heart and 
will be discussed in detail specific to this thesis in Chapter 5.  It provides diagnostic 
information about the heart’s function and internal structure (Bonow et al., 2011).  
 
As outlined previously, due to the increasing number of venesection clinic patients being 
referred for echo and the extended echo waiting list, the author decided to investigate whether 
echoes were warranted for the HH patient population.   
 
In order to answer this, the clinical background behind why gastroenterologists made a 
request for echo contra to the BSE Guidelines as outlined earlier, had to be uncovered.  
Furthermore an understanding of why this gastroenterology problem was becoming a 
cardiology problem needed investigation.   
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Iron hypothesis of cardiovascular disease causes controversy.  Aursulesei et al. (2014) 
recently suggested that this subject has been controversial for 30 years.  They state many 
studies support iron’s role in cardiovascular disease whilst other studies found no evidence in 
iron as a risk factor.  This paradox supports the purpose for this thesis and lends further 
confidence in the validity of the audit and the proposed secondary research. 
 
2.3 Audit Background 
Patient data relating to a cohort of 878 HH patients attending the LCH venesection clinic was 
audited to determine the validity of the echo requests.   
 
The purpose of the venesection clinic is for phlebotomy or bloodletting to reduce the level of 
serum ferritin (storage iron) to a maintenance level.  A serum ferritin maintenance level 
ensures that the patient’s iron levels remain within the expected normal range required for 
any individual.  According to Davey et al. (1954) this treatment has been in existence since 
the 1940’s.   
 
Iron levels in the blood are evaluated using biochemical markers i.e. serum ferritin, 
transferrin saturation and iron itself.  Once the iron levels in the blood are reduced by 
phlebotomy to maintenance levels, the patients are no longer at risk of iron overloading and 
thereby not at risk of cardiomyopathy.  This fact ties in with the ACC guideline referred to 
earlier. 
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Brandhagen et al. (2002) state that, “Life expectancy is usually normal if phlebotomy is 
initiated before the development of cirrhosis or diabetes mellitus.”  Jacobs et al. in 2007 
reiterate this stating that:  
“Classical hereditary haemochromatosis (HH) is a disease relating to iron overload 
with an increase in physical symptoms over time, leading to organ failure and poor 
survival,”  
and adds one salient point: that treatment of HH is very easy and requires removing excess 
iron by phlebotomy or bloodletting and thus “preventing the disease and increasing survival.”   
Hahalis et al. (2005) similarly state there is evidence that supports this and with sufficient 
medical therapy, IOC can be reversed when it is diagnosed prior to end stage heart failure. 
 
To place this secondary research in context, it is important to depict how the relational 
elements regarding HH and the heart’s physiology were interlinked.  Fig. 2.3 depicts a mind 
map of these relational elements. 
 
Fig. 2.3 Relational Elements of the Venesection Audit and the secondary research 
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In addition to the secondary research, which gave a holistic view of the interrelations between 
venesection, HH, echo, blood, iron and heart physiology, a road map was envisaged and the 
audit actions were drawn up.   
 
The audit actions roadmap consisted of a venesection patient database focusing on: age; 
gender; serum ferritin levels at diagnosis; serum ferritin levels at the time of echo; actual 
echo results of the patients and patient co-morbidity.  The fundamentals of each category 
were examined so that a grasp of how all the interlinked elements related to the conclusion.   
 
The next step was to gain Health Service Executive Ethics Committee approval to ensure that 
all research was obtained ethically and anonymously (see appendix 2).  This was sought, and 
upon receipt of approval to proceed, the research data was collated.  A database of 878 
patients was created to allow the collection and analysis of the patient record data.  The 
planned outcome of this research was to ensure that the LCH Guidelines could be reviewed 
and improved with this evidence based data.   
 
The outcome of this retrospective patient record audit would be to design a protocol for 
selecting or deselecting patients for echo who have HH.  The main purpose of the project was 
to investigate and gather data, in the form of a patient record audit, of the list of patients 
attending the venesection clinic at LCH.  
 
From a customer (patient/doctor/HSE) viewpoint, this research has redefined hospital 
protocol ensuring that patients, who required echoes, received them in a timely manner and 
that appropriate resources were applied, cost effectively, resulting in achievement of efficient 
patient and clinical outcomes. 
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In conclusion, this dissertation was written from a learning outcome/research perspective and 
has retraced the steps that were necessary to understand HH, how it affects the physiology 
and myocardium of the heart and in turn what echo results would be expected and what echo 
results were actually reported.   The data obtained was retrospective and spanned a number of 
years.  This dissertation will also discuss the outcomes of the research and suggest some 
recommendations as a result of the data obtained. 
 
2.4 Chapter Summary  
 
Chapter two has given an overview of the reasons for the decision to pursue an audit of 
patient records of the HH population attending the LCH Venesection Clinic and sought to 
gain an understanding of why these patients were reviewed for echo. 
 
Literature research was undertaken to identify the various facets of the disease and of 
expected clinical outcomes anticipated from echocardiography.  This literature research 
helped to structure the thesis and give a full and balanced view of both a gastroenterology and 
cardiology in relation to the very prevalent Northern European and Irish disease that is HH. 
 
In the next chapter Haemochromatosis was defined and reviewed in terms of its history, its 
penetrance, and prevalence in populations and hones in on its most common form: Type I 
Hereditary Haemochromatosis (or classical HH).  Type I HH is this most prevalent 
haemochromatosis in Ireland and this thesis main focus.  
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CHAPTER 3 : HEREDITARY HAEMOCHROMATOSIS – CURSE OF 
THE CELTS! 
3.1 Introduction 
 
Hereditary Haemochromatosis is the most common genetic disorder among Caucasians, 
predominantly those of Northern Europe with Celtic or Nordic ancestry, “with a prevalence 
of approximately 1 per 220-250 individuals” (Adams et al.; 2005; Kowdley, 1999).  Feder et 
al. (1996) suggest carrier frequency is estimated at one in ten individuals of Northern 
European extraction.  In Ireland carrier frequency is one in five (Nicholson; 2013).  
Nicholson (2013) states that, “over 93% of Irish HH patients are homozygous for the HFE 
gene C282Y.” 
 
“Hemochromatosis may be divided into primary (or genetic) hemochromatosis and secondary 
hemochromatosis” (Zakim and Boyers, 2011).  Primary or classical HH is associated with 
two mutations in the HFE gene namely; C282Y and H63D as explained in chapter one.  
 
To fully understand HH, a review of Haemochromatosis literature commenting on a range of 
definitions and the genetic mutations causing this disorder is required.   
 
To appreciate the complexity of this disease, blood and its relationship with iron distribution 
and hepcidin, which regulates iron homeostasis, is reviewed in chapter four.  While in chapter 
five cardiac and more specifically echocardiographic manifestations of HH and how both of 
these subjects relate to one another in the treatment of HH patients is reviewed.  The logical 
approach of these secondary research topics is demonstrated below in Fig 3.1. 
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Fig. 3.4 An overview of literature review topics and their relationship with this study 
 
3.2 Hereditary Haemochromatosis Defined 
 
The Centres for Disease Control and Prevention (www.cdc.gov) state succinctly that 
“Haemochromatosis is about iron.” 
 
However, from a research and clinical perspective a range of definitions from eminent 
scholars must be reviewed in order to fully appreciate the complexity and simplicity of 
Haemochromatosis. 
Chapter three 
Genetics 
Chapter three 
Chapter four 
Iron 
Hepcidin 
Chapter 
four 
Chapter 
five 
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A world leading expert on Haemochromatosis, Pietrangelo, defined it in 2006 as follows: 
“Hemochromatosis or Hereditary Hemochromatosis should be defined today as a 
hereditary iron loading disorder, multi genic in nature, caused by a genetically 
determined failure to prevent unneeded iron from entering the circulatory pool and 
characterized by progressive parenchymal iron overload with potential for multi organ 
damage and disease.” 
 
Pietrangelo (2010) shortened this definition of Haemochromatosis to “a well-defined 
syndrome characterized by normal iron-driven erythropoiesis and the toxic accumulation of 
iron in the parenchymal cells of the liver, heart and endocrine glands.” 
 
Pietrangelo (2015) also goes on to mention that it is recognised that haemochromatosis can be 
attributed to partial or total loss of the activity of hepcidin, a small cysteine-rich antimicrobial 
peptide hormone synthesized by the liver.  This hormone controls iron entry into the 
bloodstream.  Hepcidin is discussed more thoroughly in chapter four. 
 
Allen et al., (2008) go on to define HH as an inherited condition of dysregulated iron 
absorption that can lead to total-body iron overload with secondary tissue damage in a wide 
range of organs and that iron overload related disease in patients with HH is characterised by 
“the presence of cirrhosis, severe fibrosis, hepatocellular carcinoma, or arthropathy and 
C282Y homozygosity.” 
 
The Powell et al., (2005) definition is similar stating HH “is a primary inherited disorder of 
iron metabolism leading to progressive iron loading of parenchymal cells of the liver and 
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other organs with diverse clinical manifestations, including cirrhosis, diabetes and skin 
pigmentation.” 
 
Britton et al., (2002) repeats the same stating that “Hereditary hemochromatosis (HH) 
comprises several inherited disorders of iron homeostasis characterized by increased 
gastrointestinal iron absorption and secondary tissue iron deposition.”  Andrews (2008) 
expands on this definition and states that the “dysregulated intestinal iron absorption is 
mediated at the level of the duodenal enterocyte.” 
 
It is quite clear that there is little variation and no substantive dispute in the definition of HH 
by the leading experts in the field.  Comparing these definitions, a number of salient points 
are common and all definitions describe a disease process; namely iron overloading or toxic 
accumulation and possibly organ damage.   
 
Lauffer (1991) describes Haemochromatosis as a “disorder of iron metabolism... described as 
one of modern medicine’s biggest oversights.”  An oversight because there is ambiguity 
around the symptoms and patients are often misdiagnosed because the symptoms are 
common and non-specific.  On the other hand, Griffiths (2011) suggests a low index of 
clinical suspicion is advisable to avoid delays in diagnosis which could lead to iron overload 
and ultimately organ damage.   
 
Although these are not the conventional definitions of Haemochromatosis, the literature 
points to possible controversy over not only its diagnosis but also over the risk of developing 
the disease and furthermore over the prevalence of the higher end risks of the disease.  
Beutler et al., (2002) state that the “fully expressed disease with end-organ manifestations is 
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seen in fewer than 10% of these individuals.”  This ambiguity also spills into the management 
of the disease and hence the question posed initially in this thesis: is an echo warranted in the 
HH population at LCH venesection clinic based on the current guidelines or is there a need 
for change? 
 
So, now a firm understanding of what HH is and its possible effects on this group of 
individuals has been established.  The definitions provided above are all relatively recent in 
comparison to the history of Haemochromatosis which has its origins going back thousands 
of years.  The next element geneticists are interested in is where the mutation came from. 
 
 
3.3 A Brief History of Hereditary Haemochromatosis  
 
Taking a look back chronologically, Haemochromatosis has its origin founded in the 
Neolithic or New stone age: “the Northern European hunter gatherer diet with traditional 
iron-rich high dependence on mammals and/or shellfish shifted to heavy dependence on 
grains and milk products in the Neolithic” (Straus 1977; Cordain et al., 2000; 2002).  
McCullough et al. (2015) hypothesises about the fact that “positive selection for 
Hyperferritinemia (HFE) began during or after the European Neolithic with the adoption of 
an iron-deficient high grain and dairying diet and consequent anemia, a finding confirmed in 
Neolithic and later European skeletons.” 
 
Crowe (2009) states that researchers from the Mater Hospital say it happened 50 generations 
ago, about 900 AD.  Raha-Chowdhury and Gruen (2000) contradict this theory and suggest 
that the HFE gene as found has “23 mutations in 730 meioses, suggesting an age for the 
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original C282Y mutation of approximately 200-250 generations earlier, or roughly 6,000+ 
years ago, assuming 30 years per generation.” 
 
Despite these contradictory opinions from approximately 5000-4000 BC to 150 years ago, 
this Neolithic condition found its way through time and Haemochromatosis was first 
described by Dr. Armand Trosseau (1885), a French physician, as “cirrhose portale avec 
diabete bronze” or portal cirrhosis, diabetes mellitus and bronze skin pigmentation or ‘bronze 
diabetes.’  The actual naming of Haemochromatosis is attributed to a German scientist, Von 
Recklinghaussen (1889) who named it from: "hemo" for blood and "chroma" for color, 
referring to the characteristic bronze skin pigmentation from iron overload. 
 
Sheldon, (1935) recognised that Haemochromatosis was caused by excess iron deposition and 
that it was hereditary. Then in the 1970’s Simon et al. described the genetics of 
haemochromatosis autosomal recessive disorder of the short arm of chromosome 6 encoding 
the human leukocyte antigen (HLA-A*3) also known as (HLA)-A3 complex.  The World 
Health Organisation Nomenclature Committee for Factors of the HLA system renamed HLA 
as HFE (hyperferritinaemia), (Bodmer et al., 1997).   
 
The Hyperferritinaemia (HFE) gene or ‘haemochromatosis gene’ was identified by Feder and 
his colleagues in 1996.  Zhou et al., (1998) demonstrated proof of the HFE gene when 
“knockout of the mouse HFE gene resulted in iron overload.”  These breakthroughs sparked a 
new era of discovery and in 2001 the hormone hepcidin was noted to be deficient in HH 
patients.  This hormone is essential for the control of the body’s iron balance.  In its absence 
HFE or iron overload results.  Hepcidin will be discussed in further detail in chapter four. 
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3.4 Genotyping Haemochromatosis 
Earlier it was mentioned that various mutations exist in relation to Hereditary 
Haemochromatosis.  The two most prevalent mutant alleles associated with 
haemochromatosis are the C282Y and H63D variants (Merryweather et al., 2000). 
However, classification of Haemochromatosis is dependent on a number of different factors: 
genetic profile, method of inheritance and onset age.  Confusion can occur when describing 
this condition as there are a number of generic names, for example: Classic HH; 
Haemochromatosis Type 1; Major HH; or minor HH.   A distinction also needs to be made 
because Haemochromatosis can be primary HFE, primary non–HFE or secondary 
Haemochromatosis.   
There are also four types of Haemochromatosis and associated genes as listed in Table 3.1.  
For the purposes of this thesis, Type I is being considered primarily as it is the most common 
form.  It is known as Classic HH and can be defined as “an autosomal recessive iron-overload 
disorder associated with mutation of the HFE gene, which is located on chromosome 6” 
(Feder et al., 1996). 
Primary Hereditary Haemochromatosis (Type 1) is associated with a gene defect that is 
inherited.  Secondary Haemochromatosis or secondary iron overload is not inherited and the 
cause of iron deposition is due to another disease.  Secondary Iron overload is caused by iron-
loading anaemias, parenteral iron overload, chronic liver disease and miscellaneous causes 
(Nicholson, 2013).  Juvenile hemochromatosis is caused by a mutation in the HJV gene.   
Neonatal hemochromatosis is an autoimmune disease.  See appendix 3 for an expanded list of 
Classification of Iron Overload Syndromes.    
 
   
 22 
Type of Primary 
Haemochromatosis 
Common Name Associated gene and 
gene product 
HFE/Non-
HFE 
Type 1 Classic haemochromatosis HFE (HFE) HFE 
related 
Type 2A Juvenile haemochromatosis HFE2 (hemojuvelin 
or HJV) 
Non-HFE 
related 
Type 2B Juvenile haemochromatosis HAMP (hepcidin) Non-HFE 
related 
Type 3 Tfr2-related 
haemochromatosis 
Tfr2 (transferrin 
receptor–2) 
Non-HFE 
related 
Type 4 Ferroportin-related iron 
overload 
SLC40A1 
(ferroportin) 
Non-HFE 
related 
 
Table 3.1 Classification of iron overload syndromes.   
Source: Adapted from Fig. 3 Hand Book of Liver Disease, Dand and Kowdley chapter 16    
 
Fig. 3.2 adapted from (Jacobs et al., 2007) graphically demonstrates the five stages of HFE 
related HH (Type 1) together with the various strategies for screening HH. It illustrates the 
effects of elevated serum iron parameters i.e. elevated serum transferrin saturation (TS) and 
serum ferritin (SF) and its prevalence within the population.  Beginning at stage 0 where 
there are no symptoms, biochemical nor clinical.  Over time this migrates to increases in 
transferrin saturation, then adds increases in serum ferritin with no clinical symptoms but 
then moves to the more serious clinical symptoms affecting quality of life and then finally 
onto stage IV where clinical symptoms can manifest in organ damage and early mortality.   
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Accompanying these biochemical and clinical symptoms we have general population 
screening, family screening where a family member with C282Y has been found to carry the 
gene, and then targeted screening.  Screening will be touched on later.   
 
 
Fig. 3.5 Five Stages of the HFE related Hereditary Haemochromatosis  
Source: Adapted from Jacobs et al., 2007.  
 
There are a number of significant points in relation to HH that makes an individual more 
susceptible to iron overload.  As a result these iron overload individuals are at an increased 
risk of a cardiac manifestation.  These cardiac manifestations present usually after the fourth 
decade when iron overload becomes apparent in an undiagnosed individual.  This 
accumulation takes years as a person with HH absorbs only a small amount of iron each day 
in excess of the body’s needs.   The body normally stores about 4 g of iron. 
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The real iron deposition occurs after 40 years of accumulation when to the body iron stores 
have reached 15 g to 40 g see Fig 3.3.   This is investigated more fully in chapter four. 
    
This storage occurs “in parenchymal cells of the liver, pancreas and heart liable to result in 
organ damage.  The clinical onset usually appears after midlife, and the clinical outcomes and 
severity of the disease varies considerably." (Niederau et al., 1999).  It is worth noting that 
“Men with type 1 or type 4 hemochromatosis typically develop symptoms between the ages 
of 40 and 60, and women usually develop symptoms after menopause,” (US National Library 
of Medicine, 2016). 
 
                       Age in years 
Fig. 3.6 Iron Stores and Hereditary Hemochromotosis: Relationship between total body 
iron stores and clinical manifestations of HH over time.  
Source: Brandhagen, D., Fairbanks, V., Baldus, W., (2002)  
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Three longitudinal population screening studies in which patients were followed for more 
than 20 years have shown that disease progresses in only a minority of untreated patients with 
HFE C282Y (Olynyk et al., 2004; Andersen et al., 2004; Allen et al., 2008).  Some subjects 
with compound heterozygosity (H63D/C282Y) or H63D homozygosity (H63D/H63D) also 
present with abnormal iron parameters, or even increased deposits of hepatic iron, but these 
patients usually have disease cofactors (Gurrin et al., 2009; Ramakrishna et al., 2013).  
 
The cardiac manifestations of iron overload include diastolic dysfunction that can progress to 
Cardiomyopathy.  These shall be discussed in chapter five in more detail.   
 
The various genes related to haemochromatosis types and secondary iron overload have been 
discussed.  However, focus must be drawn to the fact that to be diagnosed with HH, the 
patient must have not only a genotype but also a phenotype (physical characteristic).  This is 
graphically represented in Fig. 3.4. 
 
Fig. 3.7 Genotype and Phenotype. 
Source: Adapted from desktop article Fletcher and Halliday (2002) 
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Fig. 3.4 illustrates a generic mechanism through which patient diagnosis can be made.   When 
a patient presents with abnormal iron studies or symptoms of HH, blood tests are used to 
assess the biochemical markers of iron overload, namely: transferrin saturation (TSat), serum 
ferritin (SF) and liver function tests (LFT). If these tests demonstrate the TSat marker is 
greater than 45%, genetic screening blood tests are used to confirm the existence of the 
C282Y or H63D mutation(s).  The result could be homozygous, heterozygous or the patient 
could be a carrier.  In the case of the LCH venesection clinic patients, they have blood tests 
and genetic screening requested by their General Practitioner service or the hospital inpatient 
or outpatient’s service. 
 
The symptoms and biochemical markers described in Fig 3.4 are considered to be the 
physical characteristics or phenotype of the disease.  In order to be diagnosed with HH both 
the phenotype and genotype must be present.   
 
The genotype refers to the genetic makeup.  Genes are carried within chromosomes.  In 
humans, each cell has 46 chromosomes.  These are divided into 23 pairs, one copy from each 
parent.  As Feder et al., (1996) state, “Classic hereditary hemochromatosis is an autosomal 
recessive iron-overload disorder associated with mutation of the HFE gene, which is located 
on chromosome 6.”  Autosomal recessive means that the presence of either gene (C282Y or 
H63D) is required from both parents to have the chance of a child developing the HH disease.  
So at “conception each child of parents who are both carriers have a 1 in 4 (25%) chance of 
being an unaffected non-carrier; a 2 in 4 (50%) chance of being a carrier and a 1 in 4 (25%) 
chance of inheriting the condition,” based on the Hardy-Weinberg Equation 
(www.geneticseducation.nhs.uk).  Fig. 3.5 illustrates family screening and the possible 
genetic outcomes previously described. 
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Fig. 3.8 Family Screening and Possible Genetic Outcomes 
Source: Adapted from Haemochromatosis diagnosis, John Hopkins https://gi.jhsps.org/ 
 
In molecular genetic analysis terms, this will be described as a patient being either 
homozygous for the C282Y mutation, written as C282Y/C282Y in the Hyperferritinemia 
(HFE) gene or H63D/H63D (homozygous for H63D mutation) in the HFE gene.  
 
Compound heterozygotes written as C282Y/H63D have one HFE gene mutation from one 
parent and one from the other.  Patients can also be carriers having only one copy of the HFE 
gene mutation.  The carrier molecular genetic analysis result would be written as C282Y/n or 
H63D/n depending on which HFE mutation is carried.  HH is predominantly associated with 
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the C282Y mutation and to a lesser extent H63D mutation.  The HFE gene will now be 
focused on.  “The hemochromatosis gene, HFE, is located on chromosome 6 in close 
proximity to the HLA-A locus,” (Bittencourt et al., 2002).  Merryweather et al. (1997) 
describe the two mutations C282Y and H63D.  The HFE gene encodes a 343 amino acid 
complex class 1 type molecule.  Feder et al., (1996) clarify this further by describing the HFE 
gene defect and is a “G - to –A missense mutation leading to a substitution of tyrosine for 
cysteine at amino acid position 282 of the protein product (C282Y)” at nucleotide 845 of the 
HFE gene (Fig. 3.6) or a mutation leading to a substitution of ‘histidine at amino acid 
position 63 (H63D)’ at nucleotide 187 of the HFE gene (Fig. 3.7).  
          
Fig. 3.9 Major Hyperferritinemia (HFE) associated polymorphism C282Y: 
Chromosome 6, the HLA-A gene and the locus of the C282Y mutation   
Source: https://www.jhmicall.org/GDL_Disease. 
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Fig. 3.10 Minor Hyperferritinemia (HFE) associated polymorphism H63D: 
Chromosome 6, the HLA-A gene and the locus of the H63D mutation   
Source: https://www.jhmicall.org/GDL_Disease. 
3.5 Prevalence in the general Irish population 
Prevalence is the percentage of a population that is affected with a particular disease at a 
given time (www.merriam-webster.com). 
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HH is the most prevalent inherited disease in Ireland and in fact Ireland has the highest 
reported prevalence of HH in the world (Ryan and Crowe, 2010).   According to Crowe 
(1998) over 93% of Irish HH patients are homozygous for the HFE gene C282Y mutation.  
Crowe (2009) from the Mater's Liver Unit says the spread of haemochromatosis "around the 
world is associated with the Irish Diaspora."   Nicholson (2013) describes haemochromatosis 
as “an autosomal recessive disorder of iron metabolism, and the most common genetic 
disease in Europe.” Limdi and Crampton (2004) add that “it affects the Caucasian population 
with a prevalence of between 1 in 200 and 1 in 500 with an even higher prevalence likely in 
the Irish population.”  More recent data by Bacon et al. (2011) state that HH occurs in 
populations of northern European origin with Celtic or Nordic ancestry; with a prevalence of 
1 per 220–250 individuals.   
 
The subject of HH has been examined by researchers throughout the world and a more 
comprehensive a study could not be found than a recent publication from the European 
Association for the study of Liver Disease (EASL) in the Journal of Hepatology.   
 
Using a meta-analysis of 36 studies, examining 127,613 individuals from 22 countries the 
EASL Clinical Practice Guidelines highlight the prevalence of the common HFE 
polymorphism in the general population as shown in Appendix 4.   In this study the major 
HFE polymorphism C282Y, was found in 1 in 260 individuals or 6.2% (in the pooled cohort 
of 127,613) whilst the minor polymorphism H63D, was found in 14% (in a pooled cohort of 
170,066).  Similarly, Branhagen et al. (2002) reiterate these findings by suggesting that one 
in 250-300 white persons is homozygous for the haemochromatosis gene mutation and add 
that one in 10 is a carrier.  Douabin et al. (1999) spoke of 10% to 12% of people from a 
European decent being heterozygous for HH, with 1 in 300 being homozygous.  Gochee et 
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al., (2002) state that the polymorphism in HFE, H63D, has a higher prevalence in the general 
population (mean allelic frequency ∼14%) and is less subject to geographic variation, but it 
seems to have no clinical penetrance.  
 
Adams et al., (2005) analysed the results of 99,711 individuals in the Hemochromatosis and 
iron Overload Screening (HEIRS) study in the USA.  In a subset of Caucasian participants, 
3359 men and 2416 women had prevalence of potential iron-loading HFE genotypes (defined 
as C282Y homozygote, C282Y/H63D compound heterozygote, or H63D homozygote) was 
10% and 12% in men and women, respectively. 
 
3.6 Prevalence in clinically recognised Hereditary Haemochromatosis 
 
Having examined the prevalence of the disease in the general population, the prevalence of 
the disease in the haemochromatosis population was reviewed.  In 1935 Sheldon opined that 
“it may be accepted that Haemochromatosis is a rare disease.”  In 1955 Finch and Finch 
raised the profile of Haemochromatosis by suggesting that idiopathic Haemochromatosis is 
present “once in about 7000 hospital deaths” and in general “once in about 20,000.”  In the 
mid 1990’s Feder et al. (1996) stated that HH “affects some 1 in 400 and has an estimated 
carrier frequency of 1 in 10 individuals of Northern European descent.” 
 
In the 2010 EASL Clinical Practice Guidelines for HFE Hemochromatosis, a meta-analysis 
of 32 studies with 2,802 individuals with iron overload (clinically recognised 
haemochromatosis) is put forward demonstrating the prevalence of C282Y homozygosity 
(C282Y/C282Y) was 80.6% (in a pooled cohort of 2,802) and compound heterozygosity 
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(C282Y/H63D) was 5.3% (see Appendix 5 for the prevalence of C282Y homozygosity and 
C282Y/H63D compound heterozygosity in clinically recognized hemochromatosis, J hepatol: 
2010). 
The prevalence of these genes was analysed by this thesis.  Merryweather et al. (2000) note 
that the frequency of C282Y in Northern Europeans is “between 5 % and 10%” with C282Y 
homozygotes “accounting for between 1/100 and 1/400.”  These figures compare with that 
proposed by Adams et al. (2005) indicating a prevalence of HH of 1/220 and 1/250. 
 
Geographically, there are disparities across Europe’s regions.  Fig 3.8 adapted from European 
Association for the Study of Liver disease (EASL) shows such disparity in the C282Y allele 
(mutation).   
 Fig. 3.11 Frequency of the C282Y allele in different European Regions 
Source: EASL Clinical practice guidelines for HFE Haemochromatosis (2010) 
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3.7 Penetrance of the disease  
Penetrance is the percent frequency with which a dominant or homozygous recessive gene or 
gene combination manifests itself in the phenotype of the carriers (www.merriam-
webster.com) or the proportion of individuals of a particular genotype that express its 
phenotypic effect in a given environment. 
 
The penetrance of the disease was established to determine who may in fact be susceptible to 
actual iron overload and thereby warrant an echo being performed.  This question is at the 
centre of this thesis problem statement.   
 
From the data assessed in this literature review, the general consensus is quite variable.  
Edwards et al. (1998) state that “although the time required to become iron loaded is variable, 
it is clear that most homozygotes will eventually become symptomatic.”  It is worth pointing 
out this case is so only if left untreated, as once diagnosed, symptoms can be arrested if 
appropriately managed. 
 
According to the Irish Haemochromatosis Association (2013) HH has incomplete penetrance 
which means that not all those with the HFE gene and its associated mutations have 
developed the disease but only carry mutations of the HFE gene.  As pointed out earlier, they 
do not have HH until both the phenotype (iron overload) and genotype are identified. 
 
Neghina and Anghel (2011) completed a comprehensive meta-analysis examining 3,572 
article titles pooled from 43 study populations.  They found that phenotypic penetrance could 
not be extrapolated to the population in general. Beutler (2001) proposes that in every 
disorder, individuals with the equivalent genotypes have different clinical phenotypes even 
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though their mutant genotype is identical and suggests that there are three potential 
explanations for the variable penetrance, namely: epigenetic, environmental and genetic. 
 
Although the prevalence is high the actual penetrance or risk of developing iron overload is 
low.  According to the Oregon Health Sciences University, evidence suggests that of the 
C282Y polymorphism group, 60-90% is susceptible to iron overload disease but the risk is 
not well defined.   Also compound heterozygotes (C282Y/H63D) have a very low risk of 
developing iron overload; patients heterozygous for C282Y (C282Y/n) or H63D (H63D/n) 
have a very low risk of developing iron overload at approximately 0.5-1.0%.  Homozygous 
H63D (H63D/H63D) patients also have a very low risk of developing iron overload: less than 
0.2%.   
 
Brissot et al. (2008) state that  
“some confusion in the literature is related to an imprecise definition of 
hemochromatosis penetrance.   It has become clear that the full-blown form of the 
disease (especially with cirrhosis) is rare (probably only a few per cent of C282Y 
homozygotes).”   
He goes on to state that  
“C282Y heterozygosity, H63D heterozygosity and H63D homozygosity may not be 
responsible for increased plasma iron parameters in the absence of cofactors 
accounting for disturbed iron metabolism (especially alcoholism or polymetabolic 
syndrome),” (Brissot et al.,2008). 
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Fig. 3.12 Phenotypic variability of HFE (type 1) HH.  5 scale grading.   
Tf Sat (transferrin saturation) = 45 %: ferritin = 300 ug/L (male): 200 ug/L (female).  
Quality of life symptoms = asthenia, arthropathy; Life = life threatening symptoms = 
cirrhosis, diabetes, Cardiomyopathy. 
Source: Adapted from: Brissot et al. (2008) 
 
Brissot et al (2008) provide a phenotypic five scale grading Fig. 3.9.  It lends clarity to 
penetrance in HH.  Using the scale, it would imply that “50% of all C282Y homozygotes may 
present a phenotypic profile (grade 2) justifying venesection therapy.” 
 
3.8 Chapter Summary 
 
In conclusion, there are a large number of HFE polymorphisms, however, according to 
Adams (2015) only two: C282Y and H63D appear to be clinically significant.  HH is a 
disease caused by a mutation in C282Y, H63D or both which causes iron overload.  Its 
prevalence is high in Ireland.  Although studies differ, prevalence is somewhere between 1 
per 220 to 250 individuals is commonly acknowledged.  Although penetrance is difficult to 
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quantify, its penetrance is generally thought to be low.  The hemochromatosis mutation is 
common but the hemochromatosis disease is rare (Finch and Sheldon; 1955).   
 
“The physiologic capacity to excrete iron is very limited. Thus, body iron content is 
regulated almost entirely by controlled absorption. Normal iron homeostasis is 
maintained by absorption of iron from the diet that precisely balances iron loss,” 
(Barton et al., 2011).  
 
This can cause organ damage by deposition of iron in the form of ferritin which will be 
considered in more detail in the following chapter on Blood, Iron and Hepcidin. 
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Chapter 4 : Connecting Hereditary Haemochromatosis to 
Blood, Iron and Hepcidin 
 
4.1 Introduction 
 
As stated in the previous chapter, Haemochromatosis is an iron overload disorder.  As iron is 
transported by blood, an understanding of the blood and its constituent parts in relation to HH 
needed to be elucidated.   This would lead to a better understanding of the mechanism of iron 
overload; what indeed were the best biochemical markers to use when assessing iron 
overload and thereby selection of patients for echo should iron overload be the confirmed 
diagnosis.  Therefore understanding blood, iron biochemical markers and the mechanism for 
iron overload is important in relation to data selection from the retrospective patient data 
records audit and the key data reviewed as part of this thesis.  
 
4.2 Blood: its Composition and Functions 
 
Blood is a connective tissue and as its name suggests it connects cells of parts of the body to 
the environment outside of the body.  On average, a 70 kg man would have 5.6 litres of blood 
and represents about 7% of body weight.    
The individual components of blood are red cells, white cells, platelets and plasma.  Blood 
plasma is a straw coloured substance.  This liquid blood component is:  
“a mixture of water, sugar, fat, protein, and salts. The main job of the plasma is to 
transport blood cells throughout your body along with nutrients, waste products, 
antibodies, clotting proteins, chemical messengers such as hormones, and proteins 
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that help maintain the body's fluid balance,” (American Society of Hematology; 
http://www.hematology.org/Patients/Basics/).   
It represents approximately 55% of total blood volume.  The remaining 45% of blood volume 
is represented by cells i.e. red blood cells (RBC’s) also known as erythrocytes, white blood 
cells also called leukocytes and platelets also called thrombocytes (see Fig. 4.1).     
 
Fig. 4.1 Components of the blood: Plasma 55% and cellular elements 45%.  
Source: (www.blood.co.uk) 
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The main function of white blood cells are to defend the body against infections i.e. ingest 
pathogens and destroy them; produce antibodies to destroy pathogens and produce antitoxins 
to neutralise toxins produced by pathogens.   
“Unlike red and white blood cells, platelets are not actually cells but rather small 
fragments of cells. Platelets help the blood clotting process (or coagulation) by 
gathering at the site of an injury, sticking to the lining of the injured blood vessel, and 
forming a platform on which blood coagulation can occur,” (American Society of 
Hematology; www.hematology.org/patients/basics/). 
The main function of red blood cells is to transport oxygen from the lungs and deliver it to 
other tissues and to transport carbon dioxide from other tissues back to the lungs.  Red blood 
cells contain:  
“a special protein called hemoglobin, which helps carry oxygen from the lungs to the 
rest of the body and then returns carbon dioxide from the body to the lungs so it can 
be exhaled.  Blood appears red because of the large number of red blood cells, which 
get their color from the hemoglobin,” (American Society of Hematology; 
www.hematology.org/patients/basics/).   
The distribution of iron within the blood can be seen in Fig 4.2.                 
 
Fig. 4.2 Iron Distribution in the body in males, females, children.  
Source: Adapted from U.S. Centre for Disease Control and Prevention 
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4.3 Iron and Iron Overload  
 
Comprehending the metabolism of iron underpins any consideration of its toxic effects on the 
organs.  So where it comes from, how it enters the body, what the body does with it and how 
the body gets rid of it are all relevant questions for this thesis.   
 
Dublin’s Ha’penny Bridge was Ireland’s first iron bridge; this same metal iron comprises of 
6.2% of the earth’s crust (Earnshaw and Greenwood, 2010).  It is abundant in nature and 
forms strong bonds with oxygen.  “Not long after the Big Bang, iron began to play a central 
role in the Universe and soon became mired in the tangle of biochemistry that is the prima 
essentia of life,” (Sheftel et al., 2011).  It is found in everyday use; from pots to magnets.   
 
This same metal is also fundamental to human life and without it we would die.  Iron is  
“essential for a wide range of vital cellular functions such as oxygen transport, energy 
production, and cell division.  For this reason, iron homeostasis is strictly regulated at 
both the systemic and cellular levels in order to keep iron protein-bound,” (Gammella 
et al., 2015).  
 
Hentze et al., (2010) explain this iron metabolism quite simply as being  
“balanced by two regulatory systems, one that functions systemically and relies on the 
hormone hepcidin and the iron exporter ferroportin, and another that predominantly 
controls cellular iron metabolism through iron-regulatory proteins that bind iron-
responsive elements in regulated messenger RNA’s,” (Ribonucleic Acids).   
Hentze then goes on to liken the two systems functioning and co-ordinating together like a 
biological “tango.”  
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Iron (atomic weight 55.85; atomic number 26) is a d-block transition metal (Clugston and 
Fleming, 2000) that is tolerant of biological redox reactions, having an ability to donate and 
accept electrons.  This means “as a first-row transition element, iron has incompletely filled d 
orbitals and can form a range of oxidation states.  The most common oxidation states of iron 
are Fe II (d
6
) and FE III (d
5
),” (Outten and Theil; 2009).   These common oxidation states 
allow for their incorporated use in the biological pathways of respiration, photosynthesis and 
nitrogen fixation. 
 
However, as well as being fundamental to human life, this only holds true at certain 
concentrations and the converse also holds true: greater than 40 mg/kg of elemental iron is 
toxic to humans (Manoguerra et al., 2005), which means the human body must have the 
capability to transform iron within the body to a form that is non-toxic.  So, in essence iron 
ably assists the body with its cellular redox balance.    
 
So where does this potentially life-threatening iron come from?  Back to the Universe 
question; iron is present in the soil which nourishes the plants (photosynthesis) which in turn 
nourish the animals.  Humans eat plants and animals and thereby ingest this iron through the 
food chain.  Bacon (2011) suggests that a western diet includes about 10 to 20 mg of iron 
from heme compounds of which we absorb 1 to 2 mg see Fig 4.3.  However, HH patients can 
absorb up to 3-6 mg per day and unabated this could build up to overload levels. 
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Fig. 4.3 High level review of iron and its lifecycle in the human body.   
Source: Pantopoulos K., 2012 Biochemistry. 2012 Jul 24; 51(29): 5705–5724. 
To answer the next two questions in the opening paragraph (what does the body do with the 
iron and how the body gets rid of it), the full lifecycle of iron in the body was investigated. 
Iron’s lifecycle in the human body begins when ferrous iron, also known as heme iron, is 
absorbed in the intestine through binding with Transferrin. Then transportation to the spleen, 
liver and bone marrow occurs.  Some of the transferrin binds to form haemoglobin in the 
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bone marrow.  The red blood cells (RBC’s) contain 60 to 80 percent of a human body’s iron 
and 20 to 30 percent of iron is also stored as hemosiderin in the spleen, liver and bone 
marrow, (Damjanov, 2000) see Fig. 4.4. 
Roughly 10-20mg of iron is ingested into the human body through our food chain.   
 
Fig. 4.4 Iron Metabolism.   
Source: Adapted From Damjanov, (2000). 
 
Iron is an essential “component of haemoglobin, myoglobin and enzymes necessary for 
normal cell proliferation,” (Horwitz and Rosenthal, 1999).  To elaborate on this Ross et al., 
   
 44 
(2014) state that iron is an essential component of haemoglobin, an erythrocyte protein that 
transfers oxygen from the lungs to the tissues.  Aggett, (2012) describes iron as a component 
of myoglobin, a protein that provides oxygen to muscles and supports iron metabolism, while 
Murray-Kolbe, (2010) state that iron is also necessary for growth, development, normal 
cellular functioning and synthesis of some hormones and connective tissue as it encodes 
DNA.   
Abnormal iron deposition in the cells causes oxidative damage. Serum iron, transferrin 
saturation, and ferritin have been used widely to assess iron status (Brugnara, 2003).  Iron 
(stored as ferritin and hemosiderin) has no major excretory mechanism in the body apart from 
blood loss.  Brisscot et al. (1981) suggest that there is a rapport between serum ferritin and 
total body iron stores and these markers co-relate strongly with hepatic iron stores.  This iron 
(1mg of iron per day) is needed to counteract the iron losses through sweat, shed via the skin 
and through the gastrointestinal tract.  McCance and Widdowson, (1937) stated that there is 
compelling evidence that in human beings iron excretion is greatly restricted (see Fig. 4.5). 
 
Fig. 4.5 Iron overload, pathophysiology.  Source: www.cdc.gov 
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So, in conclusion iron is required to sustain the human body.  It is ingested, bound and 
transported in the body via transferrin.  Its storage occurs in ferritin molecules but there is no 
physiologic mechanism for excretion.  Therefore, it is paramount that iron absorption and 
iron use are balanced through iron homeostasis. 
 
4.4 Iron Homeostasis 
Iron overload is caused by a genetic defect causing people to absorb excessive amounts of 
dietary iron.  The normal iron balance is maintained by a series of closely regulated by 
proteins.  In normal subjects, absorption of iron from the gut is inversely correlated with iron 
stores (Baur, 2009).  Iron is relatively difficult to absorb from the diet, resulting in only about 
10% of dietary iron (approximately 1 mg – 2mg) being taken in as shown in Fig. 4.6.  
 
Fig. 4.6 Normal iron homeostasis in humans (left) and it’s homeostatic failure in 
haemochromatosis (right). 
Source:  Pietrangelo, 2005 Hereditary Hemochromatosis, doi:10.1016/j.bbamcr.2006.05.013 
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The restriction of iron is balanced by a highly complex iron homeostasis system.  Siah et al. 
(2006) state iron absorption is dependent on the body’s iron stores, hypoxia and rate of 
erythropoiesis.  Particular methods are used both systemically and cellularly to maintain iron 
homeostasis.  Systemic iron is regulated at the transcriptional level and cellular iron balance 
is regulated by a post transcriptional mechanism (Wang et al., 2011).  Iron in the body is 
bound to the protein transferrin.  This non-saturated state ensures that iron remains in a non-
toxic form as stated by Outten and Theil, (2009) as follows:   
“In the circulation, iron is safely transported by transferrin (Tf), whose binding 
capacity is normally not fully saturated.  Body iron homeostasis is regulated by the 
interaction of the liver-derived peptide hepcidin and its receptor, the iron exporter 
ferroportin.”   
Hepcidin is discussed later in this chapter with ferroportin will be reviewed below. 
 
Cellular iron uptake occurs as a result of receptors on the cell’s plasma membrane.  These 
receptors bind iron-transferrin complexes and then allow them to enter the endosomes.  Once 
the endosomes take in the iron-transferrin complexes separation occurs.  Iron is then moved 
to the inner part of the cell.  The transferrin that remains after the separation from iron is 
called apotransferrin.   
 
This iron-free apotransferrin is able to start the iron binding process again, binding to and 
transporting iron atoms into the interior of the cells.  “The HFE protein associates with the 
transferrin receptor and prevents internalisation of the iron-transferrin complex into cells,” 
(Gross et al., 1998), that is the HFE protein effectively stops iron uptake.  However, in the 
event that there is a mutation in the HFE gene as in HH, “the mutant protein does not 
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associate with the transferrin receptor and does not dampen the iron uptake by the cells,” 
(Gross, et al., 1998).     
 
Ferroportin (FPN) is an iron exporting protein and “plays an essential role in iron 
homeostasis at the systemic level” (Samira et al., 2015).  Macrophages (white blood cell, 
antigen phagocytization and protein secretion that regulate cells involved in immune 
responses) and entrocytes (hyperpolarized epithelial intestinal absorptive cells) release iron in 
the plasma, causing iron overload.  Remember erythropoietic needs are fulfilled primarily, 
however, entrocytes continue to transfer unneeded iron from digested matter into the 
bloodstream, instead of retaining it in the form of ferritin see Fig. 4.7.  When this normal 
balance mechanism is affected iron accumulation occurs.   
 
Fig. 4.7 Normal iron homeostasis. Uncontrolled release of iron into the plasma. 
Source: engl j med 350;23 (www.nejm.org June 3, 2004) 
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Practice guidelines from the Bacon et al. (2011) on behalf of the American Association for 
the Study of Liver Disease (AASLD) state that Hereditary Haemochromatosis evolves in a 
series of three stages as opposed to the five stages put forward by (Jacobs et al., 2007) in 
chapter two, however, the overall description of the stages are similar: 
 
1. Clinically insignificant iron accumulation at approximately 0-20 years of age which 
is associated with 0-5g parenchymal iron storage. 
2. Iron overload without disease at approximately 20-40 years of age which is 
associated with 10-20g parenchymal iron storage. 
3. Iron overload with organ damage at approximately 40 years of which is associated 
with more than 20g parenchymal iron storage. 
 
As previously mentioned, duodenal (intestinal) iron uptake increases and iron overload 
begins to occur in HH patients: but how is this evaluated and diagnosed?   Bacon et al. (2011) 
suggests “the initial approach to diagnosis is by indirect markers of iron stores... namely TS 
or unsaturated iron-binding capacity and serum ferritin.”  Transferrin saturation (TS) is 
calculated using a ratio of serum iron to total iron-binding capacity.    
 
Franchini and Veneri (2005) reiterate this and state that transferrin saturation and serum 
ferritin are the most reliable tests for detecting individuals with HH.  “Serum ferritin has less 
biological variability than TS, but it has a significant false positive rate because of elevations 
related to inflammation.”  It is worth noting that as Bacon et al. (2011) reveal:  
“ferritin can be elevated in the absence of increased iron stores in patients with 
necroinflammatory liver disease (alcoholic liver disease [ALD]), chronic hepatitis B 
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and C, nonalcoholic fatty liver disease (NAFLD), in lymphomas, and in patients with 
other non-hepatic chronic inflammatory conditions.”   
Cherfane et al. (2013) also note that abnormal iron study results also occur in many liver and 
hematologic diseases.  The normal and abnormal ranges for TS and serum ferritin are 
outlined in Table 4.1 and 4.2 respectively.  Hentze et al. (2010) state:  
“in humans, plasma transferrin is normally about 30% saturated with iron.  A 
transferrin saturation <16% indicates iron deficiency, whereas >45% saturation is a 
sign of iron overload.  When saturation exceeds 60%, non-transferrin-bound iron 
begins to accumulate in the circulation and to damage parenchymal cells.” 
 
Transferrin 
saturation 
(%) 
Interpretation Action 
<16% LOW Consider iron deficiency 
 
16-45% NORMAL Reassure patient that he/she 
does not have iron overload.  
Return to usual care 
>45% ELEVATED Proceed with serum ferritin 
tests and additional workup as 
warranted 
 
Table 4.1 Interpreting the results of a fasting transferrin saturation (TS) test.  
Source: EASL, (2000), CDC Expert Panel on Hemochromatosis, 2000 and 2002.  Also, 
Hentze et al., (2010), Two to Tango: Regulation of Mammalian Iron Metabolism, Cell 142, 
July 9, Elsevier. 
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Serum 
Ferritin Levels 
(ng/ml) 
Interpretation Action 
<200 for 
premenopausal 
females OR  
<300 for males 
NORMAL Recheck every 2 years and 
reassure patient that he/she 
does not have iron 
overload. 
200-300 for post-
menopausal 
female 
BORDERLINE 
ELEVATION 
Consider other factors in 
making the 
recommendation to treat or 
observe. 
>200 for 
premenopausal 
female OR >300 
for 
postmenopausal 
female OR >300 
for male 
ELEVATED In the absence of other 
causes, removal of iron via 
phlebotomy is indicated.  
Confirmation of 
hemochromatosis is 
warranted. 
 
Table 4.2 Interpreting serum ferritin test results in patients with elevated fasting 
Transferrin Saturation.   
Source: EASL, 2000; Barton J., 2000; CDC Expert Panel on Hemochromatosis, 2000 and 
2002. 
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Jeffrey et al. (1999) state that “transferrin saturation has a sensitivity of greater than 90% for 
hemochromatosis when a phenotypic case definition is used.”  In context, Cardoso et al, 
(2014) state “the sensitivity of a test is defined as the proportion of people with the inherent 
disease who test positive (true-positive)”.  The demonstration of a high serum iron, 
transferrin-saturation (serum iron/total iron binding capacity) in excess of 60% in post-
menopausal women or 60% in men and 50% in premenopausal women with an elevated 
serum ferritin is indicative of HH.  The combination of elevated transferrin saturation and an 
elevated serum ferritin is associated with a sensitivity of 0.94 and a specificity of 0.86 in the 
detection of early hemochromatosis (John Hopkins Medicine https://gi.jhsps.org).  In context, 
Cardoso et al, (2014) state “the specificity of a test is the proportion of people without the 
disease that have a negative test (true-negative).” 
 
Once elevated serum and/or elevated transferrin saturation has been determined, confirmation 
of Haemochromatosis is warranted and a genetic test will be performed.  If both the 
phenotype and genotype are present a phlebotomy programme will be commenced.  This 
phlebotomy (also known as bloodletting or venesection) programme typically requires 
approximately 15 phlebotomies, each removing 450 ml to 500 ml of blood.  Each 500 ml of 
blood extracted removes approximately 200 mg of iron. The goal is to reduce the ferritin 
level to below 50 ng/ml (Assi and Baz; 2014).  The affects of phlebotomy have been 
researched by The U.K. Haemochromatosis Society.  They state as the number of 
phlebotomies increase, “serum ferritin decreases steadily” and the “transferrin saturation 
remains high until iron deficiency occurs,” then plummets.  Fig. 4.8 illustrates how 
therapeutic phlebotomy may affect blood iron.   
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Fig. 4.8 The Affects of Phlebotomy on Serum Ferritin and Transferrin Saturation 
Source: office@haemochromatosis.org.uk/haemochromatosis/treatment 
 
The phlebotomy process is described simply in Fig. 4.9 showing three steps.  Red blood cells 
are removed by phlebotomy which in turn stimulates the bone marrow to produce RBC’s 
(erthropoeisis) thereby reducing iron stores. 
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Fig. 4.9 Phlebotomy Treatment.   
Source: www.cdc.gov. 
 
 
4.5 Serum Ferritin   
Ferritin was discovered in 1937 by Laufberger.  He noted the presence of ferritin in the 
spleen and liver of the horse (Granick, 1943).  In 1946 Schade and Caroline showed the 
antimicrobial effect of siderophilin J, the beta-1 iron-binding globulin component of plasma 
and human serum.  This protein siderophilin was later changed to ferritin and ferritin is the 
best transporter protein for iron.  Ferritin is a high-molecular-weight protein that contains 
approximately 20% iron and present in nearly all of the body’s tissues.  It acts as an iron store 
in hepatocytes and reticuloendothelial cells.  However, in the heart “iron is deposited 
predominantly in myocardial cells, rather than in the interstitium” (Fitchett 1980).   It is also 
present in the serum acting as a surrogate for normal iron stores.  Addison et al., (1972) ably 
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demonstrated that “serum ferritin was elevated in patients with iron overload and decreased 
in patients with iron deficiency diseases.” 
 
Elevated plasma iron is represented by elevated transferrin saturation whereas elevated tissue 
iron is represented by elevated serum ferritin.  “The plasma iron overload is followed by a 
second phase, one that involves progressive accumulation of iron in the parenchymal tissues 
of the liver and other organs, as heralded by rising serum levels of ferritin,” (Pietrangelo, 
2004). 
 
Jacobs and Worwood, (1975) proposed an assay of serum ferritin might lead to a “useful and 
convenient method of assessing the status of iron storage.”  Morrison et al. (2003) state that 
marked elevation of serum ferritin level has been associated with histologic evidence of iron 
deposition. 
 
Worwood, (1986) states that ferritin is a soluble protein that provides the primary form of 
iron storage in the body.  It has an apoprotein shell encapsulating a core of iron in the form of 
ferric hydroxyl-phosphate.  It has two types of subunits; H and L.  H (heavy) subunits are 
found in the heart in the acidic isoferritins (Arosio: 1978; Powell et al.; 1975; Wagstaff et al., 
1982).  The “H refers to the original isolation of isoforms of ferritin from human heart, which 
are rich in the H subunit,” whereas the L (light) subunits “refers to ferritin isolated from 
human liver, which is rich in a lighter subunit,” (Wang et al., 2010).  Iron is stored either as 
ferritin or as hemosiderin. The former is water-soluble; the latter is water-insoluble (Beutler 
et al., 2001). 
Adams et al. (1999) state that correlation between serum ferritin and total body iron stores 
with hepatic iron concentration and the amount of iron removed by venesection is clear.  This 
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response to venesection is no longer required as evidence of iron overload due to the 
existence of genetic testing.  Serum iron can be raised as a result of chronic inflammation and 
histiocytic neoplasms.  Wish (2006) mentions that “Serum ferritin is an acute-phase reactant,” 
meaning that inflammatory states may increase serum ferritin levels suggesting iron overload.   
This is an important point to note in HH patients because the serum ferritin may be raised as a 
result of an inflammation process at work and not necessarily iron overload as discussed 
earlier in this chapter. 
 
4.6 Hepcidin 
 
Hepcidin is the body’s police mechanism for iron absorption.  As can be evidenced in the 
following, hepcidin is easily detected and lack of hepcidin is a leading cause of iron overload.   
 
Pantopoulos et al. (2012) describe hepcidin as “the master regulator of both dietary iron 
absorption and systemic iron trafficking and homeostasis.”  Hepcidin (also known as liver-
expressed antimicrobial peptide (LEAP-1)) is a protein which “can be detected in both human 
blood and urine,” (Krause et al., 2000).  According to Wish (2007) “if storage iron is elevated 
then the liver synthesises hepcidin” to assist in lowering iron levels.   
 
“Hepcidin is an antimicrobial peptide produced by hepatocytes in response to inflammatory 
stimuli and iron,” (Krause et al., 2000; Park et al., 2001; Pigeon et al., 2001).  This regulatory 
hormone polices iron transport into the plasma by binding to ferroportin on the “enterocytes, 
macrophages, hepatocytes and other cells,” (Nemeth et al., 2004).   
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Iron overload occurs when the presence of hepcidin is deficient in the blood as noted by 
Sebastinai and Pantopoulos (2011): “hepcidin deficiency... is associated with uncontrolled 
dietary iron absorption and progressive tissue iron overload.”  This was reiterated by Al 
Wayli et al., (2011) who state: “Hepcidin is an iron regulatory hormone that inhibits 
ferroportin-mediated iron export from enterocytes and macrophages.” 
 
Inappropriate levels of hepcidin, the iron hormone, appear now as the central pathogenic 
event in all forms of haemochromatosis.  The link made by Pigeon et al., (2001) between 
hepcidin and iron metabolism changed how HH was looked at.  Dallalio et al., (2003) concur 
stating “the serum hepcidin concentration exhibited a statistically significant correlation with 
serum ferritin concentrations.”  
 
The 25-amino acid antimicrobial peptide hepcidin has been shown to play a major role in iron 
homeostasis (Park et al., 2001).  In a mice study (Nicholas et al., 2001), the mice lacking this 
peptide showed progressive iron accumulation whereas over-expression of hepcidin in mice 
leads to decreased iron stores and severe microcytic hypochromic anemia at birth.  The 
upstream stimulatory factor 2 (USF2) knockout mouse, which does not express hepcidin was 
found to have iron overload resembling HH where iron deposition was significant in the liver, 
pancreas and heart. 
 
4.7 Chapter Summary 
 
In conclusion, Hereditary Haemochromatosis is an iron overload disorder caused by a 
mutation in the HFE gene.  Iron metabolism involves maintaining a fine balance.  It has been 
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established that iron overload can be determined by biochemical surrogates for iron; serum 
ferritin and transferrin saturation.  Hepcidin is fundamental in maintaining this balance.   
“The deficient production of hepcidin causes a situation resembling a tap that cannot 
be turned off.  Intestinal cells and macrophages continue to release unneeded iron, 
depleting the stores in these cellular compartments and overloading the circulatory 
pool.” (Pietrangelo, 2006).  
Phlebotomy is the approved treatment for iron overload.  If phlebotomy treatment is not 
undertaken then according to Cairo et al. (1997) the reserve iron in HH is “primarily 
deposited in parenchymal cells, with reticuloendothelial cell accumulation occurring very late 
in the disease,” as opposed to deposited in the reticuloendothelial cell (RE iron) and then 
parenchymal cells in secondary iron overload like that caused by transfusional iron overload.  
What this actually means is that a:  
“Distinction among these causes of iron deposition is clinically important because 
parenchymal iron overload from hemochromatosis may produce significant tissue 
damage, while the RE iron of transfusions and rhabdomyolysis is of little clinical 
consequence,” (Siegelman et al., 1991). 
 
While this could imply that the parenchymal cells of the heart could be infiltrated with 
storage iron leading to more drastic consequences, the actual fact is that the principal features 
of HH are decreasing over the years as evidenced in Table 4.3.  This could be due to earlier 
diagnosis, treatment with phlebotomy or a number of other factors.  
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Table 4.3 Principal Clinical features in Hereditary Hemochromatosis.  
Source: Bruce et al. (2011). Diagnosis and Management of Hemochromatosis: 2011 Practice 
Guideline by the American Association for the Study of Liver Diseases, Hepatology July: 
54(1): pg 328-343 
 
Chapter 5 will now address the link between HH, iron, the heart and what echocardiography 
can add to the clinical diagnosis and management of HH. 
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Chapter 5 : The Link between Hereditary 
Haemochromatosis, the Human Heart and 
Echocardiography 
 
5.1 Introduction  
 
As discussed in chapter three, iron is crucial to human life, specifically to our cellular 
function.  Iron deficiency can limit cardiac function in heart failure patients, a fact 
demonstrated in two major randomised clinical trials: the FAIR-HF trial and the FERRIC-HF 
trial (Anker et al., 2009).  However, the corollary to this statement is also true: too much iron 
can also have a negative impact on cardiac function.  Gammella et al. (2015) state that “iron 
accumulation in the heart plays a major role in the process leading to heart failure.” Also 
Shizukuda et al. (2006) similarly state that “patients with hereditary hemochromatosis (HH) 
have been reported to develop diastolic functional abnormalities detectable by 
echocardiography” as a result of the iron overload.   
 
The purpose of this study was to ascertain if an echo was warranted in the HH venesection 
population of LCH.  To form a conclusion on this, a definitive link between iron overload, its 
effects on the heart in HH patients and the use of echocardiography in diagnosing iron 
overload as evidenced by the available literature on the subject had to be found. 
 
Firstly, as pointed out in previous chapters, the HH genetic condition causes excessive 
amounts of dietary iron to be absorbed from the intestine and stored by the organs.   The 
patients attending the LCH venesection clinic showed signs of this as will be evidenced in 
chapter seven.  Over the course of a number of decades, the excessive storage grows to toxic 
levels as evidenced by Barton et al. (2011): “When storage mechanisms are overwhelmed, 
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iron in low-molecular weight forms can catalyze free radical reactions.”  The oxyradicals can 
damage nucleic acids, cellular lipids, proteins and carbohydrates.  This point was reiterated 
by Young et al. (1994) stating that “free iron is a potent promoter of hydroxyl radical 
formation that can cause increased lipid peroxidation and depletion of chain–breaking 
antioxidants.”  Chan et al. (2015) suggest that iron-overload generates reactive oxygen 
species (ROS) production which in turn encourages apoptosis in cardiomyocytes via 
mitochondrial pathways. Fig. 5.1 summarises this degeneration and clearly lays out that 
damaged cardiomyocytes fibrose and lead to heart failure.  
 
Fig. 5.1 Roles of iron in the pathologic progression leading to cardiac dysfunction.  
Excess iron, from systemic overload (e.g. thalassemia) or mislocalization (e.g. FRDA) 
can catalyse ROS. 
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Source: Oxid Med Cell Longev. 2015; 2015: 230182. Published online 2015 Mar 24. 
doi:  10.1155/2015/230182 
 
 
As stated in the previous chapters, Haemochromatosis is an iron overload disorder.  In the 
context of the heart, this disorder is hard to comprehend as it is primarily a gastroenterology 
problem.  A review of literature demonstrates a number of authors believe the liver is most 
affected by HH because of its large blood flow.  Obviously the heart’s function is blood flow, 
however, some writing on the matter conclude the issue of iron overload in the heart is due to 
a combination of the presence of more mitochondria and the heart’s inability to clear toxins 
like the liver.  Doroshow et al. (1980) for example state: “given the heart’s high need of 
energy, cardiomyocytes are rich in mitochondria and consume large amounts of oxygen; 
cardiomyocytes have low levels of antioxidant enzymes.”  Thus, the heart becomes a victim 
of iron, resulting in iron overload.  This iron overloading had not manifested in the LCH 
cohort examined as evidenced in chapter seven. 
 
The literature research regarding the reasons and effects of iron overload and the heart are 
central to understanding the iron overload cardiac relationship.  In this chapter a number of 
opinions, some similar and some contradictory, are investigated.  A sample from these 
opinions is highlighted below to give a sense of latitude and scope of judgment on the 
subject.  Understanding and awareness of these opinions is central to this thesis and the 
objective is to provide comprehension and clarity on the subject.   
 
In this chapter, the general introduction sets the scene, followed by iron’s effects on the heart, 
a physiological outline of the heart, phlebotomy and the heart, echocardiography and HH, and 
finally a short conclusion is provided. 
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5.2 Latitude and Scope of Judgment on iron overload and the effects on the 
Heart 
 
Witness these statements taken from the literature review as a sample of the similar and 
contradictory conclusions regarding this subject: 
“Little is known about the relationship of heart iron content to mortality.  This is 
partly because endomyocardial biopsy is impractical in routine clinical practice and is 
not a useful indicator of heart iron as a whole owing to very uneven iron distribution 
in the heart,” (Barosi et al., 1989).    
 
Modell and Berdoukas (1984) showed that post-mortem measurements of iron concentration 
in many organs, even in patients dying of heart failure, heart iron was only a fraction of that 
in the liver. 
Cutler et al. (1980) stress the importance of early recognition of Haemochromatosis heart 
disease and state that “hemochromatosis represents the only cause of a restrictive 
Cardiomyopathy that is potentially reversible by medical therapy.” 
Olson et al. (1989) assert that “Cardiac hemochromatosis represents a storage rather than an 
infiltrative disease.  This fact was proven histologically because iron was present within the 
sarcoplasm.”  Olson et al. also stated the extent of the iron varied inversely with ventricular 
function. 
“Complications, which are preventable by iron depletion therapies, can be fatal and include 
liver cirrhosis, cancer, diabetes, hypogonadism, heart failure and arthritis,” (Hentze et al., 
2010). 
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Iron Overload Cardiomyopathy (IOC) is the term used to describe the cardiac dysfunction 
that results from the accumulation of iron in the heart whether from primary or secondary 
hemochromatosis (Kreminastonis et al., 2011).  Also as stated by Cheng and Lian (2013):   
“Iron overload cardiomyopathy (IOC), defined as the presence of systolic or diastolic 
cardiac dysfunction secondary to increased deposition of iron, is emerging as an 
important cause of heart failure due to the increased incidence of this disorder seen in 
thalassemic patients and in patients of primary hemochromatosis.” 
“Several diagnostic methods have been developed in order to detect myocardial iron 
overload as early as possible, thereby averting a process that can lead to 
Cardiomyopathy, heart failure, and untimely death,” (Gammella et al.., 2015).   
T2-star magnetic resonance (MR-T2*) for example is a diagnostic tool for evaluation of 
cardiac iron status and detection of early global ventricular dysfunction (Lekawanvijit and 
Chattipakorn, 2009). 
Finally, Niederau et al. (1996) evaluated a cohort of 251 patients over a number of years and 
concluded that early diagnosis of HH, along with therapy prevent the unfavourable 
consequences of iron overload.  The LCH population cohort of 833 patients seems to concur 
with this conclusion as they too showed no signs of iron overload.  
These sample opinions are central to this thesis problem statement of whether or not HH 
should be a valid indication for an echo for patients in a HH venesection population and what 
can clinicians conclude from an echo if it was warranted.  
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5.3 Cardiac Anatomy and Physiology 
 
In order to understand the heart’s function and how it is affected by iron overload, the cardiac 
anatomy and physiology will briefly be described. 
 
Schurig et al. (1997) describes the basic cardiac anatomy and haemodynamics.  Fig. 5.2 
shows the heart has four chambers: two atria and two ventricles.  The right and left atria are 
responsible for receiving blood from the body and are low pressure chambers.  The ventricles 
are the chambers responsible for pumping blood out of the heart to the body.   
 
Fig. 5.2 The Normal Heart Structure  
Source: www.DrHeart.in (2010) 
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The right atrium takes delivery of un-oxygenated blood from the body via the inferior vena 
cava (IVC), superior vena cava (SVC) and from the heart muscle via the coronary sinus with 
mean pressures ranging from 0-6 mmHg.  The left atrium takes delivery of oxygenated blood 
from the lungs via the four pulmonary veins (the venous system).  The maximum mean 
pressure at this juncture is 12 mmHg.  
 
The ventricles pump blood into body.  The right ventricle takes delivery of un-oxygenated 
blood from the right atrium and pumps it into the low pressure system of the lungs via the 
pulmonary artery, where according to Jones and Blackwood (1992) “the systolic pressure 
should not exceed 30 mmHg.”   
 
The left ventricle takes delivery of oxygenated blood from the left atrium and pumps blood 
into the coronary arteries that supply the myocardium (during ventricular relaxation) and into 
the high pressure system (systemic circulation) via the aorta.  This cardiac cycle takes 0.8 
seconds.  The pumping out of blood is called systole and hence systolic function and the 
relaxation of the ventricle is called diastole or diastolic function.   
 
Ventricular systole comprises of two phases: isovolumic contraction (phase 2) and rapid 
ventricular ejection (phase 3).  Ventricular diastole equally has two phases: isovolumic 
relaxation (phase 4) and rapid ventricular filling (phase 1).  This is illustrated in Fig 5.3. 
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Fig. 5.3 Cardiac Cycle mechanics demonstrating the atrial and ventricle systolic and 
diastolic functions.   
Source: Silverthorn et al. (2009), Human Physiology: An Integrated Approach, Pearson 
Education. 
 
5.4 Histology – The walls of the heart 
 
Having reviewed the haemodynamics of the heart, it is important to review the internal 
structure and the microscopic anatomy because it is here where the iron deposits.  The heart 
walls comprise of the epicardium, myocardium and endocardium as shown in Fig. 5.4.    
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Fig. 5.4 Histology – the walls of the heart: epicardium, myocardium, endocardium and 
pericardial sac. 
Source: www.histologyolm.stevegallik.org 
 
The epicardium is the outer layer of the heart.  This thin, serous membrane is part of the 
serous pericardium.  The pericardium acts as a protective sac surrounding the heart.  The 
myocardium is the heart muscle layer in the middle.  The innermost layer which provides a 
smooth lining with endothelial tissue is the endocardium.  The pericardial sac is a fibrous 
tissue layer consisting of a visceral or epicardial layer of heart muscle and the parietal 
pericardial layer lining the pericardial sac.   
 
The relevance of this histology from a HH viewpoint is that HH can lead to a dilated 
Cardiomyopathy characterized by the development of heart failure and conduction 
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disturbances due to excess deposition of iron within the myocardium.  As referenced by 
Olson et al. (1987) and Palka et al. (2004) “iron-catalyzed myocardial injury leads to 
diastolic dysfunction affecting predominantly LV subepicardial layers.”  Olson et al. (1987) 
also describes how this injury begins within the epicardium, then extends to the myocardium 
and finally reaches the endocardium.  Nordberg et al. (2007) state that “Stainable iron 
assumes a sarcoplasmic localization, but precise subcellular distribution of iron has not been 
well defined.”  
 
5.5 Histology - The Cardiac Muscle Cell 
 
Cardiac muscle cells are known cardiac myocytes, which are cylindrically shaped cells with 
sizes ranging between 80-150 μm in length, and 10-20 μm in diameter (Walker and Spinale, 
1999).  The cardiac muscle comprises of sarcomeres and intercalated discs.  Sarcomeres 
contain actin and myosin filaments essential for the contractile function of the cardiac muscle 
fibre.  The intercalated discs are myocardial muscle cells responsible for conducting the 
rapidly generated cardiac electrical impulses from cell to cell (see Fig. 5.5). 
 
Fig. 5.5 depicts the anatomy of a cardiac muscle.   
(a) Histologic section of Myocardial cells 
(b) A cross-section of the internal structure of cardiac muscle cell 
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Fig. 5.5 Microscopic Anatomy of Cardiac Muscle.   
Source: Olson, L., Edwards W., McCall J., Ilstrup D., Gersh B. (1987) 
 
There is general consensus in the field regarding the method and location of iron deposition 
in the myocytes as evidenced by Horwitz et al. (1999) stating:  
“as the storage capacity of cardiac cells is exceeded, excess iron becomes released 
intracellularly as hemosiderin and free iron. This results in the formation of reactive 
oxygen species, which in turn initiates the processes of lipid peroxidation, membrane 
permeability alteration, and myocyte death.”  
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This process involves a series of different stages: apoptosis, fibrosis and cardiac diastolic 
dysfunction and dilatation.  This creates an iron storage disorder with the potential to damage 
cardiac tissue and cause functional impairment (Galiuto et al., 2013).     
 
Janower et al. (2007) are also in agreement and state “cardiac involvement in 
hemochromatosis affects mainly the myocardium: iron overload of the myocytes reduces left 
ventricular distensibility,” and causes cardiac dysfunction.  While Swanton (2003) writes that 
“increased iron absorption with iron overload results in iron deposition in the myocyte 
sarcoplasm, with subsequent cell death and fibrosis.”  This in turn leads to diastolic 
dysfunction and later to LV remodeling in the form of a dilated LV.   
 
A similar conclusion was written by Olson et al. (1987) when they assessed autopsies on the 
hearts of 14 men with Haemochromatosis: “The atria and 10 sites in the ventricles were 
histologically graded for stainable iron. Stainable iron was exclusively sarcoplasmic.” 
 
Case studies from the Massachusetts General Hospital Weekly Clinicopathological Exercises 
(1994) revealed that:  
“early in the disease process, excess iron is preferentially deposited in the ventricles. 
This manifests as progressive diastolic dysfunction consistent with restrictive 
physiology.
 
 As the disease progresses and maladaptive remodeling occurs, the LV 
dilates and systolic dysfunction develops.”   
 
Fig. 5.6 shows an example of both the histological myocardial biopsy and a cross section of a 
pathology specimen from an iron overloaded heart as described in the previous paragraphs.  
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Fig.  5.6 Hemochromatosis Histological Myocardial biopsy specimen and Cross section 
of Dilated Left Ventricle and Right Ventricle.  
Source: Olson et al.: 1994. 
A: Histologic section of myocardial biopsy specimen showing iron (black stain) within the 
myocardial cells (arrows).  B: Gross pathology specimen with the reddish-brown rust 
appearance and dilated cardiac chambers characteristic of cardiac Haemochromatosis.  LV: 
left ventricle; RV: right ventricle 
 
5.6 The Role of Phlebotomy and the heart 
 
The consequences of iron overload described above can be ameliorated by use of phlebotomy 
which “mobilizes the excess iron stored in cells, decreasing myocardial iron content and 
improving LV function,” (Dabestani et al., 1984).  This was similarly demonstrated in a study 
which showed reductions in “left ventricular dimensions and improvement in fractional 
shortening and ejection fraction in 11 primary haemochromatosis patients who underwent 
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phlebotomy,” (Candell-Riera et al., 1983).  Fig. 5.7 shows an actual example of an 
Echocardiogram of a 55-year-old woman who presented with dyspnea, fatigue and a dilated 
left ventricle (LV).  Her ejection fraction was initially severely reduced and after repeated 
phlebotomy her heart recovered. 
                         
     Left figure (Pre Phlebotomy)               Right figure (Post Phlebotomy) 
Fig.  5.7 Echo of a 55 year old pre and post Phlebotomy.   
Source: Seward et al (2010)   
 
The figures above show echoes from a 55-year-old woman who presented with dyspnea and 
fatigue.   The figure on the left shows the left ventricle is dilated, with marked systolic 
dysfunction (ejection fraction = 16%).   The figure on the right is an echo six years after 
repeated therapeutic phlebotomy (LV cavity decreased in size, and systolic function 
improved: ejection fraction = 69%), Seward et al. (2010). 
 
Alexander and Kowdley (2009) also discuss this fact demonstrating that cardiac involvement 
occurs late in the course of HFE HH and that venesection or iron depletion can improve 
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cardiac function before the development of cardiac dysfunction.  In fact, they also state that 
cardiac dysfunction is not prevalent at all due to early diagnosis and treatment of HH.  This is 
an important element in relation to this thesis argument.    
 
5.7 Iron overload and Cardiac manifestations 
 
Beutler et al. (2003) have said that only 1% of homozygotes develop clinical manifestations 
associated with HH.  He also says Clinicians do not encounter many cases of full-blown 
hemochromatosis.  HH occurs late in life as has been previously established: iron overload 
occurs in the fourth decade of life.   
Baur (2009) addresses the clinical manifestations of iron overload and states that they include 
liver disease in 75% of cases, weakness and lethargy in 74%, skin hyperpigmentation in 70%, 
diabetes mellitus in 48%, arthralgia in 44%, impotence in 45%, electrocardiographic 
abnormalities in 31% and heart failure and conduction disturbances in 15%. 
Iron deposition can cause diastolic dysfunction and Cardiomyopathy.  A Report of the 1995 
World Health Organization/International Society and Federation of Cardiology Task Force on 
the Definition and Classification of Cardiomyopathies define Cardiomyopathies “as diseases 
of the myocardium associated with cardiac dysfunction.” Haemochromatosis is more 
specifically defined as a Metabolic Cardiomyopathy. 
 
Gulati et al. (2014) remind us that iron overload is diagnosed based on serum ferritin >300 
ng/ml and a mutation in the HFE gene as previously discussed in Chapter 3.  He also goes on 
to say that diastolic dysfunction, arrhythmias and dilated cardiomyopathy otherwise known as 
primary iron overload Cardiomyopathy or Cardiac Haemochromatosis are potentially 
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reversible. These reversible echocardiographic findings associated with advanced stages of 
Haemochromatosis are also clearly defined by Oh et al. (2006) as a dilated LV with 
decreased systolic function, normal wall thickness and restrictive diastolic filling.  
 
5.8 Echocardiography 
Echocardiography as its name suggests, describes the use of “ultrasound in cardiology in 
which returning echoes are reflected from the boundaries of cardiac structures,” (Anderson, 
2004).  Echocardiography began in the 1950s with quite basic equipment.  Today’s clinicians 
have progressed and made enhancements to original techniques for measurement and analysis 
of the heart using two dimensional, three dimensional, M-mode, spectral, colour and tissue 
Doppler.   
Echocardiography images are quantitatively and qualitatively assessed and the results used by 
many disciplines.  According to the American Institute of Ultrasound in Medicine (AIUM), 
the use of echocardiography “literally became a life-changing event,” (Meyer, 2004).   
Echocardiography is safe and provides non-invasive, investigative and diagnostic cardiac 
data.  On average at least 1,200 outpatient echoes are performed in LCH each year. 
Poulsen (2001) reminds us that two-dimensional and doppler echocardiography has become a 
well accented, practical and safe non-invasive method for diagnosis of LV diastolic 
dysfunction and she also mentions that doppler flow profiles are influenced by several factors 
including age, heart rate, load conditions and valve heart diseases which must be taken into 
consideration during evaluation.   
The British Society of Echocardiography (BSE) and the American Heart Association (AHA) 
provide echocardiographers with guidelines and minimum data set requirements required 
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when evaluating the heart.  The BSE recommends this and states that the “minimum data set 
provides a template against which studies in any department should be audited.”  See 
Appendix 6 for further details. 
Palka et al. (2002) debate the usefulness of conventional echocardiography in HH patients 
with diastolic dysfunction stating that “findings are often not specific.”  In contrast to this 
Stollberger and Finsterer (2001) state storage disorders can lead to cardiac involvement 
“which can be visualized by echocardiography as all cardiac chambers may be dilated in 
advanced disease.”  They continue to say that echocardiographic findings may also be 
unspecific and may be overlooked.  While Cecchetti et al. (1991) found that 
“echocardiographic abnormalities were significantly more frequent and marked in subjects 
with higher iron overload than in those in whom it was lower.”   
When an indication for echo on a HH patient is requested, evidence of restrictive type 
diastolic dysfunction and Cardiomyopathy are sought.  Kremastinos et al. (1993) state that 
the early manifestation of cardiac involvement is the restrictive type diastolic dysfunction 
detected by doppler echocardiography.  Galiuto et al. (2012) suggest that particular attention 
should be paid to the following when assessing patients with haemochromatosis and other 
storage diseases: 
 Myocardial Texture 
 Left Ventricular wall thickness 
 Global systolic function (Teichholz and Simpson) 
 Regional left ventricular wall motion abnormalities (RWMA) 
 Diastolic function 
 Valvular function 
 Right Ventricular function 
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These measurements will be described in more detail below in relation to HH.  
 
5.8.1 Myocardial Texture   
This refers to the appearance of the 
myocardium or the myocardial 
reflectivity/brightness on 
echocardiogram see Fig. 5.8 A and B. 
 
 
 
 
 
 
 
    
Fig.  5.8 Echoes of the heart A and B contrasting echogenicity/brightness 
Source: www.revespcardiol.org 
A 
B 
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The heart in Fig. 5.8A appears brighter or more echogenic than the heart in Fig. 5.8B.  
5.8.2 Left ventricle wall thickness 
 
“Hemochromatosis appears as a dilated cardiomyopathy with normal wall thickness,” (Klein 
et al., 1998).  In a normal heart, the wall measurement will be symmetrical and measure up to 
1.1 cm (11 mm).  Echocardiographers use the parasternal long axis view (PLAX) of the left 
ventricle which allows for M-mode or 2D measurement of the left ventricle walls i.e. the 
interventricular septum and the posterior (inferolateral) wall.  Fig. 5.9 represents the 
echocardiographic structures that are visualised parasternally and transected.  This is an 
example of one of the methods of measuring the wall thickness and an actual image of wall 
thickness on 2D m-mode.   
 
The image on the left in Fig. 5.9, depicts the echocardiographic structures visualised along a 
single line (or M-mode) transmitted by the transducer located on the chest wall and 
penetrating perpendicularly the structures below.  The image on the right demonstrates the 
method of measurement of the left ventricle cardiac dimensions as recommended by the 
American Society of Echocardiography.   
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Fig. 5.9 The parasternal long axis view of the left ventricle (note EKG is an ECG).  
Source: Feignbaum, H. Echocardiography 5
th
 edition.  Lea and Febiger, pp 660, 1994. 
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Fig. 5.10 Actual normal left ventricular M-mode wall measurements (green lines)  
Source: www.stanford.edu 
 
Fig. 5.10 shows an echocardiographic screenshot from the 2D M-mode.  The two vertical 
green lines indicate the measurements being observed.  The standard measurements are 
shown in the top right of the screen and are explained as follows: IVSd – interventricular 
septum in diastole; IVSs - interventricular septum in systole; LVIDd – left ventricular 
internal diameter in diastole; LVIDs – left ventricular internal diameter in systole; LVPWd - 
left ventricular posterior wall in diastole; LVPWs - left ventricular posterior wall in systole.   
 
   
 80 
5.8.3 Systolic function  
 
Left ventricular systolic function is defined by Galiuto et al. (2013) as “the ejection fraction 
(EF), defined by the fraction of volume ejected during each ventricle contraction.”   Schiller 
and Foster (1996) add to that by stating that “Ejection fraction is probably the most 
commonly discussed clinical index of left ventricular function.”  LV systolic dysfunction 
arises when the ejection fraction is reduced. 
 
Horwitz and Rosenthal (1999) describe the hemodynamic and morphological abnormalities 
of cardiac haemochromatosis as either “dilated or restrictive” and state that early dysfunction 
is characterized by diastolic and restrictive physiology and later disease is manifest by dilated 
cardiomyopathy with left ventricular systolic dysfunction.”  They also add a salient point that 
“Moderate to severe left ventricular dysfunction is associated with heavy iron deposition in 
the heart.” 
 
Fig 5.11 is echocardiography’s most frequently used method for calculating systolic function 
by using LV volume.  It is known as the biplane method of discs (modified Simpson’s rule).  
This technique for estimating EF is recommended by the American Society of 
Echocardiography and the European Association of Echocardiography.  
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Fig. 5.11 Simpsons 2D method for calculating Left Ventricular volumes, 4 chamber and 
2 Chamber.    
Source: Lang et al. (2006), Recommendations for chamber quantification, European Journal 
of Echocardiography, 7, 79-108. 
 
Fig. 5.11 shows tracing of the endocardium in systole and diastole.  A4C = apical four 
chamber; A2C = apical 2 chamber; EDV = end diastolic volume; ESV = end systolic volume.  
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5.8.4 Diastolic Dysfunction 
 
In the context of HH, diastolic dysfunction is an early indicator of a disease process which is 
underway.  Gaasch and Little (2007) describe diastolic dysfunction as  
“functional abnormalities that exist during LV relaxation and filling.  When such 
abnormalities cause or contribute to the clinical syndrome of heart failure with a 
normal LV ejection fraction, it is appropriate to describe the condition as diastolic 
heart failure.”   
 
Quantitative measurement of diastolic function can be performed by using pulsed wave 
doppler (PW-doppler) and pulsed wave tissue doppler integral (TDI). 
 
Anderson (2004) suggests that the diagnosis of diastolic heart failure “requires three 
conditions: (1) presence of signs or symptoms of heart failure; (2) presence of normal or 
slightly reduced LV ejection fraction (EF >50%) and (3) presence of increased diastolic 
filling pressure.” 
 
Firstly, the left atrial size is an important indicator of elevated filling pressures and should be 
measured as part of the diastolic assessment see Fig. 5.12.  The left atrial (LA) volume should 
also be measured at end systole.  The LA is largest at this part of the cardiac cycle and gives 
the accurate measurement of LA volume.  Secondly, normal LV diastolic dysfunction can be 
characterised by left ventricular (LV) mitral inflow.  To measure this mitral inflow, a pulsed 
waved (PW) doppler sample volume is placed at the mitral valve (MV) leaflet tips at end 
expiration.   This inflow is a resultant velocity caused by LV suction and the pressure 
gradient between the left atrium and left ventricle.    
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Fig. 5.12 LA Volume Measurement.   
Source: http://dx.doi.org/10.1093/ejechocard/jeq164 140-147 First published online: 26 
November 2010 
 
Fig. 5.12 depicts representative images of the measurement of the left atrial (LA) volume. 
Picture (A) is an apical four-chamber view; Picture (B) is an apical two-chamber view.  
Typical measurements are of the left atrial areas in the apical four- and two-chamber views 
(A1 and A2 respectively), and the left atrial common long axis (L1).  LA volume is 
calculated using area-length method and modified Simpson's method.  
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5.8.5 Diastolic Filling Pressure 
 
There are two diastolic flow velocity envelopes that can be observed in normal sinus rhythm.  
The E wave represents early passive filling of the LV, whereas the A wave represents late 
diastolic active filling of the LV caused by the contraction of the atria (see Fig. 5.13).  
Impaired relaxation is shown in Fig. 5.14.  Abnormal mitral inflow velocities are indicated by 
the large A wave and the reduced E wave.  This indicates reversed transmitral Doppler.   
 
 
Fig. 5.13 Normal mitral inflow velocities from the left atrium with the pulsed wave (PW) 
sample volume placed at the leaflet tips in the left ventricle during diastole.  
Source: www.echobasics.de 
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Fig. 5.14 Abnormal mitral inflow velocities are indicated by the large A wave and the 
reduced E wave. 
Source: www.echobasics.de 
 
Mitral annular velocities are another method of measuring diastolic function using Tissue 
Doppler Integral (TDI); the PW sample volume is placed at the medial and/or the lateral 
annulus of the mitral valve see Fig. 5.15.  The sample volume is placed at or within one 
centimeter of the annulus.  This method is invaluable because it is not dependant on preload.   
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Fig. 5.15 Normal pulsed wave TDI.  The sample volume is placed at the lateral MV 
annulus  
Source: www.echobasics.de 
 
Fig. 5.16 TDI is suggestive of impaired diastolic dysfunction 
Source: www.echobasics.de 
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Fig. 5.16 suggests an impaired diastolic dysfunction as the E’ wave and A’ wave are reversed 
compared to Fig. 5.15. 
 
In Fig. 5.16, the expected restrictive diastolic dysfunction pattern associated with end stage 
iron overload is shown.  That is: Normal diastolic filling (E > A); delayed relaxation (E < A); 
and restrictive (E >>A) filling patterns.  For more information see Appendix 7. 
 
When assessing diastolic dysfunction (DD), multiple echocardiographic measurements 
looking at the various facets related to DD i.e. LA size, mitral inflow, TDI etc. should be 
made so that an informed decision can be reached on the DD.  An assessment based on any 
single parameter related to DD should not be made.  Refer to Appendix 8 for a practical 
approach to the assessment and grading of Diastolic Dysfunction. 
   
5.8.6 The Right Ventricle (RV) 
 
Assessment of the RV is made to establish RV systolic function and size.  Right-sided 
chamber dilatation with left ventricular dilatation can cause biventricular failure which may 
lead to classic symptoms of heart failure (Bejar et al.., 2015). 
 
5.8.7 Valvular Assessment  
 
The valves of the heart (the aortic, pulmonic, mitral and tricuspid) should always be assessed 
as part of a standard echocardiogram.   
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5.8.8 Regional Wall motion abnormalities (RWMA) 
 
Galiuto et al. (2013) describes myocardial walls according to the distribution of coronary 
arteries. The walls are divided into regions or segments and are assessed in terms of their 
systolic motion and thickening.  The regions are scored as having: normal motion, 
hypokinetic, akinetic, dyskinetic or aneurysmal.  RWMA would give an indication as to the 
severity of iron overload and could also give an indication of LV dysfunction reversal (return 
of normal LV systolic function) as a result of iron reducing therapy. 
 
 
5.9 Chapter Summary 
 
The progress in the field of understanding iron overload and the heart has shown substantial 
leaps in the 150 years since the discovery of Haemochromatosis.  The Nicholas et al. (2001) 
mice iron knock out trial has shown that iron can produce cardiac damage.  The literature 
review has shown that iron overload can be and is very treatable, essentially leaving an 
individual with HH with a normal life expectancy and little risk of Cardiomyopathy. 
 
Erhardt et al. (1999) stated “as a normal life expectancy of patients with HH can be achieved 
if iron reduction is initiated early, genetic testing may thus be of great benefit for patients 
with HH.”  Echo is a very useful method of evaluating the heart’s diastolic function and 
determining if either restrictive or dilated Cardiomyopathy is present.  
  
However, an echo should only be indicated in the event that there is a real risk of iron 
overload.  Shizukuda et al. (2011) found that in subjects with cardiac asymptomatic HH post 
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conventional phlebotomy treatment, LV diastolic function statistically did not significantly 
deteriorate during a 5-year period regardless of their treatment history.  If HH caused high 
mortality then there would be an expectation that there would be an underrepresentation of 
elderly patients with the disease.   “The life expectancy of these patients, as measured over 
the follow-up period (14 years), was indistinguishable from that of the general population, 
corrected for age and sex,” (Niederau et al., 1996). 
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Chapter 6 : Analysis of Hereditary Haemochromatosis 
Patient Cohort – Methodology Study 
 
6.1 Introduction 
The methodology employed during this study is depicted over the following sections.   
6.2 Research Process Design Overview 
The research process design overview is shown below in Fig. 6.1 and has nine formal steps.                                     
 
Fig. 6.1 The Research Process Design Overview for this study and thesis 
Steps one to seven of the process are described in this chapter.  The final two steps have 
separate chapters each as they are the focus of this thesis.  Data Collection and Review is 
presented in Chapter 7, the Discussion in Chapter 8, with Conclusions and Recommendations 
presented in Chapter 9. 
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6.1.1 Step 1: Framing a Problem Statement 
 
The objective of this first step is to frame a problem statement.  This step began with an 
anomaly being noted: generally, the overall increase in demand for echoes and specifically 
the exponential increase in demand from the LCH venesection clinic as explained in Chapter 
1.  Given the fixed capacity for echoes within the department, these increases were resulting 
in increased waiting lists as capacity requirements had surpassed its finite limit.  Allying this 
issue with patient scheduling on a first come, first served policy, thereby taking no clinical 
urgency into account, it was believed that there could be serious ramifications for patient 
welfare and waiting list management. 
This judgment in fact was confirmed by initiating an informal, high level investigation of the 
echocardiography diary for the previous twelve months.  This was the preliminary part of 
structuring the problem statement.  With this general information a problem statement was 
framed and thus formed a potential benefit analysis from which it could determine whether 
further investigation was worthy.  
 
6.1.2 The Problem Statement   
LCH has one echocardiographer with a finite capacity to provide a range of services to the 
patients and clinicians serving the LCH, Dundalk and Our Lady of Lourdes, Drogheda.  The 
total demand trend on the service had noticeably increased over the past ten years without 
any service capacity increase in line with Health Service Executive budgetary forces.   
This demand trend was noted an initial high level initial investigation of the previous years’ 
echocardiographic appointments.  It detailed that over the past decade there was an 
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exponential increase in the number of echoes being requested for HH patients from the LCH 
Venesection Clinic.  The demonstrated data trend of increased requests is shown in Chapter 1 
Fig. 1.1.  Taking 2009 as a baseline (a quantity of 13), 2014 showed a 1354% increase to a 
quantity of 189.  
When the level of service demand was related to the known capacity of the echocardiography 
department, this increase created a direct amplification in patient waiting lists.  Most 
importantly, as requests were dealt with on a first come first served basis, the relative 
importance of patient treatment needs was not being taken into account on the backlog 
waiting list.  This could potentially lead to delay of urgent echoes which could be time and 
clinically critical to a positive patient treatment outcome. 
6.1.3 Step 2: Formulation of Potential Study Objective Aims 
The objective aim of this study was to retrospectively investigate if an echo was warranted in 
the HH population at LCH Venesection Clinic.  Then, following from the conclusions of this 
study, recommend to the Gastroenterology department whether the guiding principles of LCH 
should be retained or revisited if contrary to the conclusions.   
The outcome of this study would possibly directly affect the future number of 
echocardiography requests from the HH venesection clinic and the department’s ability to 
execute and report on all warranted requests in a clinically safe timeline whilst proactively 
managing the waiting list.  
6.1.4 Step 3: Building an Hypothesis 
In order to create an hypothesis for the study to test and have a meaningful and unbiased 
review of the objective, an assessment of the primary medical field guidelines from the 
appropriate governing bodies of the British Society of Echocardiography (BSE), the 
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European Association for the Study of the Liver (EASL) and The American College of 
Cardiology (ACC) was completed as previously discussed in chapter two. These guidelines 
from the BSE, EASL and ACC were used as a basis for the thesis’ relevance to current 
practice and to rationalise and guide the study hypothesis.   
In conclusion, the governing body of Echocardiographers, the BSE, have no stated 
requirement warranting an echo to be performed for HH patients, while the EASL put 
forward an algorithm stating the need for C282Y homozygous patients only to receive an 
echo in the event that the patient is symptomatic and has increased Serum ALT, AST and 
HbA1c.  The ACC similarly have an algorithm to ascertain if an echo is warranted but only in 
patients showing symptoms of IOC, that is “systolic or diastolic cardiac dysfunction 
secondary to increased deposition of iron in the heart independent of other concomitant 
processes” (Liu and Olivieri :1994).   
Using this evidence as a starting point the following hypothesis was put forward for testing: 
For HH patients attending the LCH venesection clinic (i.e. patients who are having 
their iron overload proactively managed through phlebotomy) who have no co-
morbidities, an echo is not warranted. 
Clearly stated, if this patient type as described above does not have iron overload because it is 
being proactively managed, then the patient does not warrant an echo.  
This hypothesis is tested using historical data gathered through a retrospective LCH 
venesection clinic patient record audit.  It was hoped to prove that when HH patients with no 
other co-morbidities were treated through phlebotomy; iron overload was proactively 
managed and the results of the echoes performed would demonstrate the effectiveness of the 
treatment.  Through this proactive treatment, the onset of cardiomyopathies in HH patients 
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with no other co-morbidities had been avoided.  That is, the results would illustrate normal 
echoes with no significant cardiac abnormalities resulting from the initial HH iron overload 
diagnosis.  Therefore, for this patient cohort, echoes were not warranted and the exponential 
increase in echo requests for this patient cohort would substantially decrease, alleviating 
demand on the echocardiography department.  
 
6.1.5 Step 4: Secondary Research  
 
Now that an initial hypothesis was created, the next step was to further investigate prevalent 
theories, concepts and practice in a broad literature review as detailed in chapters two, three, 
four and five. 
A brief description on how the secondary research process was performed is as follows:  
The literature reviewed covered published books, medical journals, medical articles and 
associated medical websites.  Of particular interest were articles, experiments and clinical 
papers with similar investigations into echoes and treatment of Haemochromatosis patients 
worldwide.   
From a topical viewpoint, HH was delved into; its definition, history, genotype and 
phenotype, its prevalence and penetrance in Europe and Ireland, its symptoms and its 
treatment.  Two directly relevant observations come from this portion of secondary research.  
Firstly, that clinical evidence suggested only the C282Y polymorphism group is susceptible 
to iron overload disease (60-90%) although the risk is not well defined.  All other 
polymorphisms have a very low risk of developing iron overload.  However, in the LCH 
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venesection clinic patient cohort there were patients in the other polymorphism groups that 
had presented with iron overload.   
Secondly, the phlebotomy treatment can easily and proactively manage Iron Overload in the 
body.  In patients where no other co-morbidities are present, the result of this treatment is 
iron overload prevention.  This intervention precludes the progression of the disease thereby 
avoiding tissue damage.  Therefore, the patients of the LCH venesection clinic who present 
with no other co-morbidities should not warrant echoes to determine if there is adverse heart 
tissue damage. 
An investigation of the blood, iron absorption, the role of hepcidin, iron overload, the effects 
of iron overload on the normal heart, the physiology and anatomy of the heart and 
echocardiography was undertaken.  In this section evidence was presented which showed HH 
could lead to Iron Overload Cardiomyopathies. 
Following the literature reviews the preliminary hypothesis was revisited and then moved 
into the methodology section of research design of the LCH venesection clinic patient record 
audit.  Secondary research also continued in parallel to this activity and the hypothesis 
remained under review during this period. 
 
6.1.6 Step 5: Hypothesis Review 
In order to create a meaningful and succinct hypothesis for the study to test, the preliminary 
hypothesis was reviewed following the in-depth secondary research phase of this thesis.  The 
secondary research validated the preliminary hypothesis, that is where there are no other co-
morbidities, this patient cohort phlebotomy treatment is managing their iron overload disease 
resulting in a high probability that echoes on this cohort will be normal.  Therefore, the echo 
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report is adding little clinical value other than to confirm to clinicians the phlebotomy 
treatment is effective.   
The aim of the hypothesis must now be rewritten to state the test scenario to be proven or 
disproven.  The final hypothesis for this study was formulated as follows: 
HH patients with no co-morbidities attending the LCH venesection clinic for 
phlebotomy do not warrant an echocardiograph as their echo result will show no 
significant abnormalities relating to HH.  
The null hypothesis is the corollary statement: 
Hereditary Haemochromatosis patients with no co-morbidities attending the LCH 
venesection clinic for phlebotomy do warrant an echocardiograph as their echo result 
will have significant abnormalities relating to Hereditary Haemochromatosis.  
As stated earlier, proving or disproving this hypothesis will be tested using historical data 
gathered through a retrospective venesection patient record audit.  In doing so it was hoped to 
prove that when HH patients with no other co-morbidities were treated through phlebotomy, 
iron overload was proactively managed and the results of the echoes performed would 
demonstrate the effectiveness of the treatment.  That is, the results would illustrate normal 
echoes with no heart issues resulting from the iron overload diagnosis.  Therefore, for this 
patient cohort, echoes are not warranted and the exponential increase in echo requests for this 
patient cohort would substantially decrease.  This in turn would alleviate demand on the 
echocardiography department and decrease waiting list times. 
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6.1.7 Step 6: Research Design 
A hypothesis is an educated prediction relating to an observed event.  The observed event 
must be measurable so the hypothesis and the null hypothesis can be accepted or rejected. 
In relation to this study the hypotheses have been described.  Next, the study design will be 
elucidated; what measurements were directly relevant and why; and also from where and how 
the data was being collected, validated and analysed.  
In general the study was a retrospective patient data audit and as such can best be described 
as observational research.  The sample size was 878 patients and the method of sampling was 
purposive in nature and could particularly be described as ‘criterion sampling’ which 
involves searching for cases or individuals who meet certain criterion, for example, that they 
have had a certain disease,” (Palys; 2008).  The sampling frame (the list from which the 
potential respondents are drawn) was the HH patient cohort attending the LCH venesection 
clinic for phlebotomy.  The sampling procedure involved 100% of the patients recorded as 
attending this clinic.   
6.1.8 How the Study was Designed 
Selection of participants for this study and the methods of selection could determine the limit 
of generalisations that could be made from this study.  As this was a purposive study to 
determine whether the LCH venesection clinic patient cohort need to be echoed or not, the 
selection of participants and method of selection was quite simple.  The LCH venesection 
clinic has a list of patient attendees.  This list had been compiled over the last number of 
years as new and transfer patients were added to the venesection clinic.  The plan for this 
research study was to request access to this patient cohort list and then review the relevant 
medical data from the patient’s existing medical records.  This data would be entered into an 
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excel spreadsheet database, anonymised and used as an analysis and test tool for the 
hypotheses. 
“All research potentially raises ethical issues, and consent to proceed is required from 
relevant ethical committees before a research study can commence,” (Bowling: 2002).  
Therefore, the plan outlined above was submitted to the Health Service Executive Ethics 
Committee for approval of the retrospective patient data audit to ensure that all research was 
obtained ethically and anonymously.  The Health Service Executive Ethics Committee signed 
approval along with the ethics Committee application form is shown in Appendix 2.   Upon 
receipt of this approval to proceed data collation of the research data began.   
An Excel database of 878 patients was created from the LCH venesection clinic list to allow 
the collection of the patient record data.  The planned outcome of gathering this data was to 
test the hypotheses and present the conclusions to the Gastroenterology department so the 
LCH Guidelines could be reviewed and improved with this evidence based data.   
The audit actions roadmap consisted of a venesection patient database focusing on nineteen 
primary information categories as shown in Table 6.1. 
 
Table 6.1 Categories of Data Collected for Analysis from the Medical Record Audit 
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The Medical Record Number, name and date of birth were anonymized for the purposes of 
data protection.  The additional data categories were collected as they were central to the 
purpose of the research, that is: echo data, Ferritin and Transferrin levels, hospital transfer 
data, whether the patient had been venesected, the patient’s genetics relative to 
Haemochromatosis, Laboratory results, co-morbidities listed and symptoms.  This data is 
believed to be central to the area under investigation as evidenced throughout the secondary 
research literary review. 
The actual patient medical records were requested and over a period of six months (January 
to June 2015), reviewed and transferred the data onto an Excel database.  This Excel database 
was kept on a HSE laptop which is encrypted to protect the patient data. 
The fundamentals of each category were examined so that a grasp could be gained on how all 
the interlinked elements related to the literature review data, reports, comments and 
conclusions.  
6.1.9 Inclusion and Exclusion Criteria 
In total there were 878 patients on the LCH venesection list.  However, there were limitations 
to this study as it was retrospective in design and limited to the records available.  In some 
cases the physical patient records were not available.  These patient records were each 
requested on three further occasions during the six-month research period, but were not 
returned for filing, and therefore not available for this retrospective study.  This occurred in 
45 instances (approximately 5%) and these records were excluded from the audit.  Therefore, 
the patient records for data analysis totaled 833.   
In other cases some of the main data on Echoes, Ferritin and Transferrin levels or Hospital 
Transfer data was not noted on the patient records.  These were included in the 833 total as 
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some relevant data was recordable but not in 100% of all the 19 categories per patient record.  
The non-recordable data categories were excluded from some data analysis due to this status.  
6.1.10 Methodology 
During the previous chapters a number of objects and variables whose relationships could 
possibly have a causal nature with relation to HH and cardiomyopathies were identified.  
“Objects are regarded as variables that researchers may measure and/or control, and a 
variable is simply defined as a characteristic that may vary among the subjects or units of 
observation under study,” (Azavedo et al., 2011).   
The hypotheses required an assessment of these relationships to ascertain if they are of a 
causal nature.  It was believed that the inclusion of 833 (94.9%) of the 878 patient data 
records in the analysis is high enough to negate random errors compared to a population 
probability sample.  The non-probability sample does not involve a random selection, 
therefore is representative of the venesection clinic HH population. However non-probability 
sampling cannot depend upon the rationale of probability theory and this is worth bearing in 
mind.   
It was also believed that systematic errors could be present due to the human intervention of 
taking measurements and then recording them in a separate document or number of 
documents prior to the measurement recording being input on the patient data record.  
However, detailing the possible statistical error is beyond the focus of this retrospective 
patient record audit, and therefore is not taken into account.  All measurements in the patient 
data records are taken to be true and accurate. To ensure the author’s recording was correct, a 
random selection of ten percent of all charts were reviewed to certify correct figures were 
transposed into the database.  
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The main areas of investigation regarding measurement parameters for HH as a summary of 
the literature reviews are: HH genotype and phenotype, diagnosis and disease progression, 
iron in the blood: transferrin saturation and serum ferritin levels, the effect of iron on the 
heart, cardiomyopathies and echocardiography.  
6.1.11 Biomedical Data 
The key ‘instrument’ for this retrospective patient record audit is the patient medical record.  
With exception of echocardiography which is central to this thesis, discussion of all other 
instruments used for the measurement of the recorded data in the patient medical record are 
beyond the scope of this audit. 
The outcome of this audit would be to design a protocol for selection of patients for echo who 
have HH.  The main purpose of the project was to investigate and gather data in the form of a 
patient record audit for the list of patients attending the venesection clinic at LCH.  
From a customer (patient/doctor/HSE) viewpoint this research would hope to redefine 
prevailing hospital protocol to ensure that patients who required echoes received them in a 
timely manner where appropriate resources were applied cost effectively resulting in an 
efficient and effective service level achievement. 
In conclusion, this dissertation was written from a learning outcome/research perspective and 
has retraced the steps that were necessary to understand HH, how it affects the physiology 
and myocardium of the heart and in turn what echo results would be expected and what echo 
results were actually reported.   The data obtained was retrospective and spanned a number of 
years.  This dissertation will also discuss the outcomes of the research and suggest some 
recommendations as a result of the data obtained.   
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6.1.12 Step 7: Patient Cohort Review 
A total of 878 patients were on the LCH venesection clinic list.  Some of these patient records 
were transferred from other hospitals and this fact was noted in the Excel database.  In some 
cases full information on the patient was not transferred to the LCH patient record so not all 
patient record data could be included in the data analysis.  Where patient data was not 
included, this fact is referred to in the relevant data analysis section. 
  Fig. 6.2 Patient Age Range at Diagnosis of LCH Venesection Clinic Patient Cohort 
For example, Fig. 6.2 illustrates the age range profile at diagnosis of the LCH venesection 
clinic patient cohort consisting of 833 patient records.  There are five patients where the 
patient record data did not record the date of diagnosis; hence they are listed as ‘unknown’ 
for the purposes of analysis.  99 percent (828) of the patient records did give patient diagnosis 
date.   
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Chapter 7  : Data Collection and Analysis 
 
7.1 Introduction 
The following section presents the main data analysis regarding the LCH Venesection Clinic 
retrospective patient record data review.  Firstly, general data is presented regarding the 
patient cohort in relation to age and gender.  Then specifics of genetic profile in relation to 
HH, Serum Ferritin Range at diagnosis and at time of echo is focused on and finally the echo 
results are reviewed.  The next section will then present the main findings, with discussion, 
conclusions and recommendations of this retrospective patient record data and literature 
review in chapter 8 and chapter 9.   
7.2 Data Analysis 
As can be seen from Fig. 7.1 and in line with the general comment from the literature review, 
the LCH Venesection Clinic data analysis demonstrates the majority of patients (688) are 
diagnosed after the fourth decade in their lifecycle (83%).  This finding concurs with the 
secondary research reviewed in chapter three, Fig .3.3 (Brandhagen, D.et al 2002), and as 
evidenced in a study which stated “Men with type 1 or type 4 hemochromatosis typically 
develop symptoms between the ages of 40 and 60, and women usually develop symptoms 
after menopause,” (US National Library of Medicine, 2016).   
 
The record audit computation on age at diagnosis was made using the Date of Birth of the 
patient and the date of diagnosis per the data on the patient record.  Then each patient record 
was categorised into age range groupings of: 16-30 years; 31-40 years; 41-50 years; 51-60 
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years and over 60 years.  The date ranges were chosen with reference to the HH stages 
indicated in Chapter 3 on Hereditary Haemochromatosis. 
 
Fig. 7.1 Age at Diagnosis of LCH Venesection Clinic Patient Cohort 
 
Fig. 7.2 Age at Diagnosis of LCH Venesection Clinic Patient Cohort by Gender 
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In Fig 7.2 the overall the age profile demonstrated in the LCH Venesection Clinic data shows 
a similar age of diagnosis profile for males and females with the exception of the 31-40 age 
range, where it can be seen the male diagnosis cohort is four times (4:1) higher than the 
female diagnosis cohort where male patients outnumber females by only 2:1. 
The genetic profile of the HH patients was also reviewed.  As evidenced in chapter 3, in the 
2010 EASL Clinical Practice Guidelines for HFE Hemochromatosis, a meta-analysis of 32 
studies with 2,802 individuals with iron overload (clinically recognised haemochromatosis) is 
put forward demonstrating the prevalence of C282Y homozygosity (C282Y/C282Y) was 
80.6% and compound heterozygosity (C282Y/H63D) was 5.3% and no carrier detail was 
mentioned. 
In Fig. 7.3 the LCH Venesection Clinic data reports that 63 percent of patients were 
homozygous for C282Y (C282Y/C282Y), 9 percent were homozygous for H63D 
(H63D/H63D) and 26 percent were compound heterozygous C282Y/H63D.  So our patient 
cohort demonstrates a lower incidence rate in the C282Y allele and a much increased 
prevalence of the C282Y/H63D allele. 
 
Fig. 7.3 Genetic Profile of LCH Venesection Clinic Patient Cohort 
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From a gender perspective the breakdown of the genetic prevalence is similar in the male and 
female profiles as shown in Fig 7.4. 
 
Fig. 7.4 Genetic Profile by Gender of LCH venesection Patient Cohort 
This profile can be seen in detail in Table 7.1.  C282Y homozygous is the leading genetic 
profile with 59 percent of males and 69 percent of females carrying this gene.  The next 
largest genetic profile are the C282Y/H63D heterozygous group with 27 and 23 percent 
retrospectively, then the H63D homozygous category with males at 11 and females at 7 
percent.  
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Table 7.1 Genetic Profile by Gender of LCH venesection Patient Cohort 
Serum Ferritin levels are an agreed method of reflecting iron in the body as evidenced in the 
literature review by Jacobs and Worwood, (1975) who proposed an assay of serum ferritin 
might lead to a “useful and convenient method of assessing the status of iron storage,” while 
Morrison et al. (2003) state that marked elevation of serum ferritin level has been associated 
with histologic evidence of iron deposition.  The Serum Ferritin Range taken at patient 
diagnosis is shown in Fig. 7.5.  
 
Fig. 7.5 Serum Ferritin Range at Age of Diagnosis by Gender of LCH venesection clinic 
Patient Cohort 
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The normal Serum Ferritin range for males and post-menopausal females is 300ng/ml and 
200ng/ml for premenopausal females.    In Fig. 7.5 the data from the LCH venesection clinic 
show that at age of diagnosis 61 percent of males (345) and 50 percent of females (137: 
<201ng/ml as the age of menopause cannot be determined) are above the nominal threshold 
for normal Serum Ferritin levels.  This historic patient data is of interest as it can be 
compared to the post phlebotomy data in the next Fig. 7.6.  
 
Fig.  7.6 Serum Ferritin Range at Time of Echo by Gender of LCH Venesection Clinic 
Patient Cohort 
Fig. 7.6 demonstrates the positive effect of phlebotomy on Serum Ferritin levels in the patient 
cohort when compared to Fig. 7.5.  We can now see that 85.6 percent of females (155) and 
86.8 percent of males (323) had Serum Ferritin ranges at or below acceptable normal levels 
prior to echo.   This demonstrates the effective and positive relationship venesection has on 
iron overload Hereditary Haemochromatosis.  Compared to the Serum Ferritin Range levels 
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at diagnosis, where only 47 percent of females (127) had ranges at or below acceptable 
normal levels and 34 percent of males (193) had ranges at or below acceptable normal levels.  
Finally, echo data related to both Serum Ferritin levels and co-morbidities in patients was 
reviewed.  This is shown by gender breakdown in Fig. 7.7 (males) and Fig. 7.8 (females).  
 
Fig.  7.7 Male Echo Results with Serum Ferritin Range and Co-morbidity Status 
The literature review demonstrated that normal Serum Ferritin levels are an acknowledged 
measure of the level of iron in the body.  These normal Serum Ferritin levels have been 
presented in the data analysis review above.  Therefore, it is important to present the echo 
data analysis in relation to Serum Ferritin levels.  
A total of 553 echoes were performed on the total patient cohort of 833, equating to 66.4 
percent of the cohort.  Of these echoes, 548 patients had recorded evidence of known pre-
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echo Ferritin level data.  This equates to 65.7 percent of the total patient cohort and 98.9 
percent of all echoes performed.   
Echoes performed on males with pre-echo Ferritin status in our patient cohort totaled 367.  86 
percent of the male patient cohort (316) showed normal echo results.  Even taking into 
account male patients with co-morbidities (107), 73 percent of these male patients (78) had 
normal echoes.   
The expected echo results for patients with abnormal Serum Ferritin ranges would be for 
abnormal echoes in the majority of cases given the evidence that excessive iron is detrimental 
to heart health.  However, the audit demonstrates echo results for this cohort were mainly 
normal (39) with only five abnormal echoes.   
Our expectation of these 39 normal echoes would be the majority should also not have co-
morbidities associated with them and this also holds true in 30 (76.9%) of these normal 
echoes.   
Only 51 (13.9%) echoes demonstrated abnormal results.  Of these, five patients with 
abnormal serum ferritin ranges had echo findings which were not specific to HH: one patient 
had a prior surgery (an Aortic valve replacement); one patient with had left ventricular 
hypertrophy; another patient had mild aortic stenosis; the fourth had a probable bicuspid 
aortic valve; and finally, one finding of mild aortic annular calcification.  The patients 
mentioned here had increased ferritin at diagnosis and at the time of echo.  Three of the five 
patients were C282Y/C282Y, one was H63D/H63D and one was C282Y/H63D. 
Reviewing abnormal echoes in patients with normal ferritin at the time of echo and no co-
morbidity (19), the main echo results showed mildly reduced left ventricular function and 
mild left ventricular hypertrophy.  These findings are similar to those patients with abnormal 
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echoes, a co-morbidity and normal ferritin (27).  There does not appear to be a direct 
correlation between the ferritin at diagnosis, the ferritin at the time of echo, the lack of co-
morbidity and the echo results.  
These 27 patients (normal serum ferritin at the time of echo with a co-morbidity with 
abnormal echo results), echo results were abnormal as would be expected.  These results do 
seem to be related to the comorbidity and echo findings which were not specific to HH.  85% 
of this patient cohort had hypertension +/- another comorbidity i.e. ischemic heart disease, 
diabetes mellitus, atrial fibrillation, obesity and hypercholesterolemia.  Most the patients 
exhibited more than one co-morbidity in this patient cohort. 96% (26/27) were >50 years of 
age.  It is noteworthy to mention that in a normal population of adults >50 years of age in the 
Republic of Ireland the prevalence of hypertension is 64% (www.publichealth.ie.) This 
represents a higher than normal average but this was looking specifically at those patients 
with comorbidities.  
As this patient audit review was based specifically on ferritin levels and their interaction with 
echo findings, it would be worth revisiting this data focusing on metabolic syndromes and 
HH in future research. 
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Fig.  7.8 Female Echo Results with Serum Ferritin Range and Co-morbidity Status 
Echoes performed on females with pre-echo Ferritin status in our patient cohort totaled 180.  
89 percent of the patient cohort (161) showed normal echo results.  Even taking into account 
patients with co-morbidities (50), 82 percent of these patients (41) had normal echoes.   
Patients with above normal Serum Ferritin ranges were mainly shown to evidence normal 
echoes (18) compared to 7 with abnormal echoes.   
Taking a closer look at the data in Fig. 7.8, those patients with normal echoes, one or more 
comorbidities and normal serum ferritin range noted that 30/32 or 98% had hypertension. 
This was the main comorbidity.  The majority (29/32) of this patient cohort were >50 years of 
age.  In a normal population of adults >50 years in the Republic of Ireland the prevalence of 
hypertension is 64% (www.publichealth.ie), as previously mentioned. 
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Reviewing the data from the abnormal echo results.  It would be expected that abnormally 
high ferritin may lead to abnormal echo results related to HH.  Those five patients with 
normal serum ferritin, one or more comorbidities and an abnormal echo had the following 
echo findings: three patients had mild left ventricular hypertrophy and hypertension along 
with additional comorbidities (hyperlipidemia, obesity, hyperthyroidism and non-insulin 
dependent diabetes mellitus); one patient had mild to moderate left ventricular hypertrophy 
and associated hypertension; and finally, one patient had at least mild pulmonary 
hypertension and mild mitral regurgitation features associated with congestive heart failure. 
This particular patient had normal ferritin at diagnosis and normal ferritin at the time of the 
study.  These findings are most likely not specific to HH given that all recorded serum ferritin 
levels have been within the normal range.  All of the patients in this cohort were >60 years of 
age. 
The four patients with abnormal serum ferritin, one or more comorbidities and an abnormal 
echo had the following echo findings: one patient demonstrated low normal function in 
association with hypertension and left bundle branch block; on patient exhibited mild left 
ventricular hypertrophy associated with hypertension and hypercholesterolemia: a third 
patient showed mild mitral stenosis with mild-moderate left ventricular dysfunction with 
atrial fibrillation and hypercholesterolemia; and finally, one patient had borderline left 
ventricular hypertrophy associated with hypertension and an abnormal liver profile. These 
echo findings were most likely co-related with the patient comorbidities.  All of this patient 
cohort was >50 years old. 
Finally, reviewing the patient cohort demonstrating abnormal echoes with no comorbidities 
and comparing the echo findings of those with normal and abnormal serum ferritin (10).  The 
echo findings were not specifically related to HH.  In fact, the echo findings for the most part 
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were unpredictable, with left ventricular hypertrophy as the main finding.  In this cohort 90% 
of the patients were > 50 years of age.  
Consolidating all echoes performed (male and female) where Serum Ferritin Level data was 
present and targeting patients with no co-morbidities only, we can see from the LCH 
Venesection Clinic data analysis that 92 percent of echoes (358) show normal results even 
when above normal Serum Ferritin levels are recorded, see Fig. 7.9.   
 
Fig. 7.9 Echoed Patients with Serum Ferritin and No Co-morbidities 
7.3 Presentation of Findings 
The highlighted data analysis from the retrospective patient record audit of the LCH 
Venesection Clinic has been presented in the previous section.  However, before launching 
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into this study’s findings and conclusions, a recap on this journey’s origin and the purpose of 
this retrospective study will follow. 
In Chapter 1 and 2 and sections 6.1.1 and 6.1.2 of chapter 6, the reasons for commencing this 
study were presented.  This journey’s origin was due to an exponential increase in the number 
of echoes being requested for HH patients from the LCH Venesection Clinic.  The 
demonstrated data trend of increased requests showed a 1354% increase over a five year 
period from 2009 to 2014 (Fig. 1.1). 
The objective aim of this study was to retrospectively investigate if an echo was warranted in 
the HH population at LCH Venesection Clinic and recommend to the Gastroenterology 
department whether the guiding principles of LCH should be retained or revisited if contrary 
to the conclusions.  
The outcome of this study would possibly directly affect the future number of 
echocardiography requests from the HH venesection clinic and the echocardiography 
department’s ability to execute and report on all warranted requests in a clinically safe 
timeline whilst proactively managing the waiting list. 
In preparation for the study, current guidelines from the British Society of Echocardiography 
(BSE), the European Association for the Study of the Liver (EASL) and The American 
College of Cardiology (ACC) were assessed.  In conclusion, the BSE does not make any 
provisions for HH patients per se; the EASL Guidelines for HH refer specifically to 
symptomatic homozygous C282Y patients only, while noting that glycated hemoglobin 
(HbA1c), serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
should first be reviewed and if symptomatic, only then should echocardiography be 
performed; the ACC state those ‘at risk’ of IOC need echocardiography.  Conversely, it was 
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suggested that those not ‘at risk’ of IOC do not require echocardiography, and as it has been 
shown through the literature review the incidence of IOC due to HH is extremely rare. 
Extensive secondary research literature reviews were then carried out in Chapters 3 to 5.  In 
Chapter 6, the storyboard of the study’s progression from its origins towards formulating a 
hypothesis to be tested was established. The hypotheses set out in step 5 (section 6.1.6) will 
now be revisited, then tested against the gathered data, findings summarised and discussion 
and conclusions presented. 
The final hypothesis for this study was formulated as follows: 
Hereditary Haemochromatosis patients with no co-morbidities attending the LCH 
venesection clinic for phlebotomy do not warrant an echocardiograph as their echo 
result will show no significant abnormalities relating to Hereditary 
Haemochromatosis.  
The null hypothesis is the corollary statement: 
Hereditary Haemochromatosis patients with no co-morbidities attending the LCH 
venesection clinic for phlebotomy do warrant an echocardiograph as their echo result 
will have significant abnormalities relating to Hereditary Haemochromatosis.  
The first argument to disprove the null hypothesis and supporting the H1 hypothesis flows 
from Fig. 7.5 and 7.6 which demonstrate the positive effect of phlebotomy on HH iron 
overload patients.  Comparing HH patients with normal Serum Ferritin Range levels at 
diagnosis, (60 percent of female and 34 percent of male patients) to the post phlebotomy/pre-
echo levels (93 percent of female and 87 percent of male patients) reveals encouraging 
management of the iron overload phenomenon.  These indications display the role of 
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phlebotomy in ensuring patients with HH preclude disease progression to the harmful iron 
overload cardiomyopathies.   
Therefore, if the HH patients Serum Ferritin levels are being managed to ensure no iron 
overloading occurs, then the HH phlebotomy patients may no longer require repeat echoes as 
the very low incidence of IOC’s due to HH is now virtually non-existent.  
Following on from this data analysis on proactive iron overload management, the focus 
moves to study the H1 hypotheses in essence: echo results for HH patients with no co-
morbidities. 
As can be seen in Fig. 7.7 and 7.8, the data to the left of the green demarcation lines on both 
male and female echo results show “normal echoes.”  This status illustrates that of patients 
with recorded Serum Ferritin at time of echo (548 echoes), 87 percent (477) resulted in a 
“normal echo” report.   
Coming closer now to the H1 hypothesis and reviewing only echo reports for those patients 
with no co-morbidities (390 patients), we can review Fig 7.7, 7.8 and 7.9.  This patient sub-
category indicates that 92 percent of echo reports (358) were “normal echoes.”  This is true 
for both patients with Serum Ferritin levels in the normal (319) and above normal (39) 
ranges. 
Therefore, the preliminary conclusion is the H1 Hypothesis is proven 92 percent of the time: 
Hereditary Haemochromatosis patients with no co-morbidities attending the LCH 
venesection clinic for phlebotomy do not warrant an echocardiograph as their echo 
result will show no significant abnormalities relating to Hereditary 
Haemochromatosis.   
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Chapter 8 : Discussion on LCH Hereditary 
Haemochromatosis Audit  
8.1 Discussion of Findings 
As stated in chapter 1, the initial investigation phase began with a review of the LCH 
guidelines in comparison with authorities in echocardiography (BSE), cardiology (ACC) and 
hepatology (EASL).  No consistency of opinion from the three authority guidelines was 
evident.  Therefore, this study’s hypothesis is of relevance in furthering practitioner 
understanding of the area through providing research of pertinent clinical data in order to 
inform and qualify current LCH guidelines on the usefulness of echo diagnostics in this HH 
venesection population.  
Further to the overall literary research and the specific data analysis in chapter 7, the BSE 
assertion is to base the recommendation for performing echoes on clinical studies.  It makes 
no provisions for HH patients per se and listed indications do not mention HH as an 
indication for Echocardiography.  Therefore, the BSE is correct and an echo should not be 
performed in conditions for which there is no clinical study evidence and generally no 
accepted role, (WWW.bsecho.org). 
Regarding the ACC algorithm for assessing patients who are ‘at risk’ of Iron Overload 
Cardiomyopathy (IOC), suggesting that an echo with full diastolic function assessment 
should be undertaken, the data analysis has shown the proactive phlebotomy management of 
HH patients is precluding iron overload and its potential to cause IOC.  Additionally, 
“although cardiac failure is a recognised complication of severe iron overload, it is clinically 
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unusual except in juvenile HC,” (EASL; 2010).  Therefore, this assessment will not be 
relevant to this particular patient cohort. 
The EASL algorithm refers specifically to symptomatic homozygous C282Y patients only, 
and therefore their algorithm is not relevant to non C282Y patients in our study.  So, for the 
C828Y patients only, the EASL state that if Serum Ferritin levels are normal – an annual 
follow up is proposed.  This would indicate that patients already participating in the 
phlebotomy programme would not require a further echo.  Also, where Serum Ferritin levels 
are increased an echo should only be warranted according to clinical features (EASL; 2010).  
Therefore, the clinical features, rather than the diagnosis of HH should influence the need for 
an echo.  This conclusion is reiterated by the EASL stating that cardiac symptoms should be 
investigated by the cardiologist. 
Reviewing the LCH venesection clinic data it was found that 67 percent of patients were 
male, 33 percent female (Fig 7.2).  According to Genetrack, one of the largest DNA testing 
facilities in North America (www.hemochromatosisdna.com), this result is expected:  
“Although both men and women can inherit the gene defect, men are more likely than 
women to be diagnosed with HH at a younger age.  On average, men develop 
symptoms and are diagnosed between 30-50 years of age.  For women the average 
age of diagnosis is about 50.”   
Diagnosis of both males and females however, seems to be later in the Irish lifecycle in 
comparison to these US figures.   
The age profile indicated that 83% of the LCH venesection clinic patients had their diagnosis 
after their fourth decade as predicated by Brandhagen et al. (2002).  In the case of age at 
diagnosis profile Fig. 7.2, it was found that there was a significantly lower incidence of 
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diagnosis age in women in the 31-40 age category compared to men in this category.  Again 
it was noted in commentary on this area throughout the literature review that this 
retrospective study concurs with this finding: “Men with type 1 or type 4 HH typically 
develop symptoms between the ages of 40 and 60, and women usually develop symptoms 
after menopause,” (US National Library of Medicine – 
(www.ghr.nlm.nih.gov/condition/hereditary-hemochromatosis).  These figures tie more 
closely to the LCH data analysis than the US data in the previous paragraph. 
Looking at the HH genetic profile of the patients and comparing them to the literature 
reviewed in chapter 3, in particular to the Irish College of General Practitioners (2013), the 
overall prevalence in Ireland is gauged at over 93 percent for the homozygous C282Y allele.  
However, in general Europe demonstrates that 80.6 percent are normally homozygous for 
C282Y allele.  In another large study in Newfoundland and Labrador (Kelley et al: 2014) 
between January 1999 and January 2009, totaling 4,138 individuals; 8.8% were C282Y 
homozygotes, 4.1% were H63D homozygotes, 6.4% were compound heterozygotes.  Again, 
this confirms the prevalence of HH in northern European populations compared to other parts 
of the world as shown in Fig. 3.8.  
Surprisingly the LCH Venesection Clinic data demonstrates a lower than expected incidence 
of C282Y homozygotes of 63% against the European average and nearly double the 
percentage for H63D homozygotes (9%) than the European average.  This case could 
possibly be a subject for further research.   
Taking into account the various stages of disease progression in HH patients as previously 
discussed in chapter 3, the patients attending LCH with no evidence of co-morbidities and 
ferritin levels within normal limits, fall into stage I (Fig. 3.2): “venesection treatment will 
allow tissue iron to be mobilized and iron stores will return to normal,” 
   
 121 
(www.haemochromatosis-ir.com).  This ties in with the recommendations as it demonstrates 
that where Serum Ferritin levels are being proactively managed, patients can lead a 
practically normal lifecycle with evidence that approximately 8 percent of patients with no 
other co-morbidities would have abnormal echoes. 
To conclude this study, similarities and anomalies have been uncovered when relating the 
LCH HH venesection population to other similar studies.  In general the data is aligned to 
that of previous studies.  Overall the conclusion is a positive assertion that venesection is a 
successful, non-intrusive management tool for HH regardless of age of diagnosis, although 
serious complications are more apparent where HH is not diagnosed early.  The use of 
echocardiography in this population could be decreased as the majority of the HH 
venesection patients were shown to have normal echoes. 
The average cost of an echo in Ireland is approximately €230 based on a review of the VHI 
average costing. The opportunity cost of 319 echoes performed (with normal echo and no co-
morbidity) is approximately €73,370. It is worth noting that echo service capacity remains 
constant irrespective of the indication on the request form. The price of an echo is not costed 
per se in LCH hospital on a case by case basis, however, the HSE are beginning to implement 
Activity Based Costing in certain sectors of the hospital.  Therefore, removing this cohort of 
patients from the echocardiography waiting list would have an effect of reducing the number 
of echoes completed in the 2014 figures (Figure 1.1) from 189 to 8.  From a pure cost 
perspective this could demonstrate a saving of €41,630 in 2014 alone and equates to roughly 
a month of echo man hours freed up.  
The implication of adjusting the local echo policy extends beyond cost. There is more to 
value than just money. The 319 echoes performed equates to approximately 8 weeks of 
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workload at the LCH cardiology department and 319 patient administrations and follow-ups 
performed by other HSE staff.   
As there was no prioritisation or vetting of echo requests in the past prioritisation on the echo 
out-patient list would have a positive knock on effect from the patient outcome viewpoint. 
There would be a reduction in the waiting list and patients would receive a more timely 
service possibly reducing the progression of a negative clinical outcome.  
Subsequent to this audit the findings were presented to the venesection team and 
gastroenterologists in LCH.  Both of these stakeholders agreed that subject to these findings 
they have decided to amend the local echo policy regarding the HH patient cohort.  In future 
echoes will only be performed on patients with serum ferritin levels above 1,000 ng/ml. 
This outcome will positively affect the echo waiting lists in LCH and result in improved and 
more focussed use of the limited resources of the Cardiology Department. 
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Chapter 9 : Conclusions and Recommendations from the 
LCH Hereditary Haemochromatosis Audit  
 
9.1 Conclusion 1: The Study Hypothesis holds true and current LCH 
Guidelines need to be revised  
9.2 Conclusion 2: The LCH venesection clinic age of diagnosis data 
generally follows previous study results 
9.3 Conclusion 3: The Genetic Profile of the LCH venesection clinic data 
demonstrates lower than expected incidence of C282Y allele but higher 
than expected H63D allele incidence compared to previous study results 
9.4 Conclusion 4: The LCH venesection clinic data demonstrates for 
patients with no co-morbidities, where Serum Ferritin levels are 
proactively managed through venesection, patients can lead a practically 
normal lifecycle 
9.5 Conclusion 5: A significant and positive cost and patient service 
improvement could be achieved if the recommendations of this study were 
to be implemented 
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Recommendation 1 – Guiding Principles 
The recommendation to the Gastroenterology Department that the guiding principles of LCH 
with regard to echocardiographic requests for HH patients with no co-morbidities who are 
attending the LCH Venesection clinic should be reappraised.  This recommendation was 
accepted. 
 
Recommendation 2 – HH Echo Patient Referral Pathway 
The recommendation that there is no clinical reason for the LCH Venesection Clinic cohort 
containing patients with no co-morbidities and normal serum ferritin levels is to be put 
forward for echocardiography is valid.  This recommendation was accepted. 
 
 
Recommendation 3 – Further Research 
 
The study recommendation is for the venesection clinic to instigate and maintain the database 
for this patient cohort.  This recommendation was accepted. 
An additional element noted during this audit would be to possibly research the patient 
comorbidities in more detail focussing on metabolic syndrome and its relationship with HH.  
This is for future discussion with the Gastroenterology Department. 
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Appendices 
Appendix 1 British Society of echocardiography - Indications for 
echocardiography 
http://www.bsecho.org/indications-for-echocardiography/  
British Society of echocardiography - Indications for 
echocardiography 
Indications  
1. Heart Murmurs 
1.1 Indicated. 
a. Murmur in the presence of cardiac or respiratory symptoms. 
b. Murmur in an asymptomatic individual in whom clinical features or other investigation 
suggest structural heart disease. 
1.2 Not Indicated. 
a. Assessment of an innocent murmur diagnosed by a competent physician. 
b. Unchanged murmur in an asymptomatic individual with previous normal echocardiogram. 
  
2. Native Valvular Stenosis 
2.1 Indicated. 
a. Initial assessment of aetiology and severity, ventricular size and function 
b. Repeat assessment of known stenosis with change in clinical status. 
c. Periodic repeat assessment of asymptomatic individual with known severe stenosis for 
ventricular size and function 
d. Repeat assessment of known stenosis in pregnancy 
e. Assessment for pre-procedural decision-making for valvular intervention (e.g. suitability 
for balloon valvuloplasty) 
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f. Periodic repeat assessment of asymptomatic individual with moderate stenosis for valve 
severity, ventricular size and function. 
2.2 Not Indicated. 
a. Periodic repeat assessment of asymptomatic individual with haemodynamically-
insignificant lesions, eg mitral annular calcification. 
  
3. Native Valvular Regurgitation 
3.1 Indicated. 
a. Initial assessment of aetiology and severity, ventricular size and function 
b. Initial assessment and risk stratification of individual with clinical signs of mitral valve 
prolapse 
c. Repeat assessment in known regurgitation with change in clinical status. 
d. Periodic repeat assessment of asymptomatic individual with known severe regurgitation for 
ventricular size and function 
e. Periodic repeat assessment of asymptomatic individual with known mild or moderate 
regurgitation and ventricular dilatation or dysfunction 
f. Periodic repeat assessment of asymptomatic individual with moderate MR 
g. Repeat assessment of known regurgitation in pregnancy 
h. Assessment for pre-procedural decision-making for valvular intervention (eg suitability for 
mitral valve repair - consider TOE and RT3D) 
3.2 Not Indicated 
a. Periodic repeat assessment of asymptomatic individuals with trivial or mild regurgitation 
and normal ventricular size and function. 
b. Periodic repeat assessment of asymptomatic individuals with mitral valve prolapse and no 
or mild MR. 
  
4. Prosthetic Valve Assessment 
4.1 Indicated. 
a. Baseline assessment of newly implanted prosthetic valve. 
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b. Late post-intervention re-evaluation for ventricular remodelling. 
c. Repeat assessment of prosthetic valve with change in clinical status. 
d. Repeat assessment of prosthetic valve with clinical findings suggestive of dysfunction 
e. Repeat assessment of prosthetic valve following exposure to clinical risk of valve 
thrombosis 
f. Periodic repeat assessment of asymptomatic individual with bioprosthetic valve (after 7 
years for aortic bioprosthesis; after 5 years for mitral bioprosthesis) if intervention without 
symptoms would be undertaken. 
4.2 Not Indicated 
a. Periodic repeat assessment of asymptomatic individual with mechanical prosthesis 
b. Repeat assessment of patients whose clinical status precludes therapeutic intervention 
  
5. Infective Endocarditis 
Note: In view of the possibility of both false-negative and false-positive studies, 
echocardiography should supplement but not replace clinical and microbiological diagnosis. 
5.1 Indicated. 
a. To characterise valvular lesions, haemodynamic consequences and ventricular response in 
a patient with clinically proven or suspected endocarditis. 
b. Detection of high-risk complications, eg fistula, abscess, mass lesions. 
c. TOE evaluation of patients with a high clinical suspicion following negative or equivocal 
TTE in native and prosthetic valves. 
d. Persistent bacteraemia of unknown source, particularly in staphylococcal infection 
(consider TOE). 
e. Baseline assessment of valve, ventricular size and function prior to discharge following 
completion of treatment for endocarditis. 
5.2 Not Indicated. 
a. Fever with no other suggestive features. 
b. Periodic repeat assessment in a clinically stable patient with prior echocardiographic 
evaluation to assess response to therapy. 
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6. Ischaemic Heart Disease - Known or Suspected 
6.1 Indicated. 
a. Chest pain with haemodynamic instability 
b. Murmur following acute or recent myocardial infarction. 
c. Assessment of infarct size, presence of complications and baseline LV function following 
MI consider use of LV contrast echocardiography) 
d. Evaluation of patients with non-diagnostic ECG and indeterminate laboratory markers if 
performed during or immediately after cardiac chest pain. 
e. Evaluation of LV function to guide further therapy or assess effect of intervention, e.g. 
drug therapy, ICD implantation, CRT, patients scheduled to undergo coronary artery by-pass 
surgery. 
g. Stress echocardiography to assess reversible ischaemia, myocardial viability and risk 
stratification. 
6.2 Not Indicated. 
a. Evaluation of non-cardiac chest pain 
  
7. Cardiomyopathy 
7.1 Indicated. 
a. Clinical cardiomegaly 
b. Clinical or radiographic signs of heart failure 
c. Unexplained shortness of breath in the absence of clinical signs of heart failure if 
ECG/CXR abnormal 
d. Persistent hypotension of unknown cause 
e. Suspected cardiomyopathy based on abnormal examination, ECG, or family history in first 
degree relative 
f. Baseline LV function and periodic review when using cardiotoxic drugs, eg herceptin 
g. Repeat assessment in documented cardiomyopathy with change in clinical status 
h. Repeat assessment in documented cardiomyopathy where result may change management 
or following procedures affecting function, eg cardiac resynchronisation, septal ablation. 
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7.2 Not Indicated. 
a. Minor radiographic cardiomegaly in the absence of symptoms or signs of heart failure. 
b. Routine repeat assessment in clinically stable patients in whom no change in management 
is contemplated. 
c. Assessment of patients with oedema, normal venous pressure and no evidence of cardiac 
disease. 
  
8. Pericardial Disease 
8.1 Indicated. 
a. Suspected pericarditis, pericardial effusion, tamponade or constriction 
b. Suspected pericardial effusion or bleeding (post-surgery or trauma) 
c. Periodic repeat assessment of moderate or large pericardial effusion 
d. Repeat assessment of small pericardial effusion with change in clinical status 
e. Echo-guided pericardiocentesis 
8.2 Not Indicated. 
a. Repeat assessment of small pericardial effusion without clinical change. 
b. Pericardial friction rub following uncomplicated MI 
c. Follow-up studies in patients with terminal illness whose management would not be 
affected by echocardiographic abnormalities 
  
9. Cardiac Masses 
9.1 Indicated 
a. Embolic peripheral or neurological events suggesting intracardiac mass 
b. Haemodynamic or auscultatory findings suggesting intracardiac mass 
c. Periodic repeat assessment following removal of cardiac mass/tumour, eg myxoma 
d. Known primary malignancies where echocardiographic surveillance for cardiac 
involvement forms part of the normal staging process, eg renal hypernephroma 
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9.2 Not Indicated. 
a. Patients with terminal illness whose management would not be affected by 
echocardiographic abnormalities 
  
10. Pulmonary Disease 
10.1 Indicated. 
a. Lung disease with clinical suspicion of cardiac involvement (cor pulmonale) 
b. Suspected or established pulmonary hypertension 
c. Suspected or established pulmonary embolism to inform a decision regarding thrombolysis 
d. Evaluation for surgical procedures for advanced lung disease including transplantation 
e. Repeat assessment of pulmonary artery pressure to evaluate response to treatment for 
pulmonary hypertension (consider saline contrast enhancement) 
f. To distinguish cardiac from non-cardiac causes of dyspnoea when the results of clinical and 
other diagnostic testing are ambiguous 
g. Patients with known chronic lung disease and unexplained desaturation (consider saline 
contrast echocardiography) 
10.2 Not Indicated. 
a. Lung disease with no clinical suspicion of cardiac involvement 
  
11. Neurological Disease 
11.1 Indicated. 
a. Acute interruption of blood flow to major peripheral or visceral artery 
b. Unexplained stroke or TIA without evidence of prior cerebrovascular disease or without 
significant risk factors for other cause (consider saline contrast echocardiography by TTE or 
TOE). The importance of a PFO if found when performing contrast studies may depend on 
the patient's age and may therefore only be appropriate in those under 55. 
c. Patients for whom a therapeutic decision will depend on outcome of echocardiography, eg 
anticoagulation 
d. Assessment of neuromuscular diseases associated with cardiac manifestations, eg muscular 
dystrophies, mitochondrial myopathies and periodic paralyses 
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e. Hemiplegic migraine (saline contrast study) 
11.2 Not Indicated. 
a. Patients in whom echocardiography will not affect decision to commence anticoagulation 
(eg patients in AF with cerebrovascular event and no suspicion of structural heart disease) 
  
12. Arrhythmia, Palpitations and Syncope 
12.1 Indicated. 
a. Clinical suspicion of structural heart disease in proven arrhythmia 
b. Assessment of ventricular function for primary prevention of sudden cardiac death (SCD) 
post-MI 
c. Assessment of ventricular function for secondary prevention of SCD in VT 
d. Evaluation of LV function prior to anti-arrhythmic medication 
e. Syncope in a patient with clinically suspected heart disease 
f. Exertional syncope 
g. Syncope in a patient with high-risk occupation, eg pilot, bus driver 
h. Assessment of patients without clinical suspicion of structural heart disease who have an 
arrhythmia commonly associated with structural heart disease 
i. Guidance of catheter placement during radiofrequency ablation (consider TOE or 
intracardiac echo) 
j. Post-operative evaluation of patients following RF ablation and surgical procedures in the 
absence of complications 
12.2 Not indicated 
a. Palpitations without proof of arrhythmia or clinical suspicion of structural heart disease 
b. Isolated premature ventricular contractions in absence of clinical suspicion of structural 
heart disease. 
c. Classic neurocardiogenic syncope 
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13. Echocardiography Before Cardioversion 
13.1 Indicated 
a. Guidance for decision to attempt cardioversion, eg LV function, MV disease 
b. Patients requiring cardioversion with AF >48hours duration not adequately anticoagulated 
(TOE) 
c. Repeat assessment of documented appendage thrombus (TOE) 
d. Repeat assessment following embolic event at previous cardioversion (TOE) 
e. Patients with AF less than 48hrs duration and clinical suspicion of structural heart disease 
not adequately anticoagulated (consider TOE). 
f. Patients undergoing cardioversion for atrial flutter 
13.2 Not indicated 
a. Patients requiring emergency cardioversion 
b. Patients on long-term anti-coagulation at therapeutic level with no clinical suspicion of 
structural heart disease 
c. Patients on long-term anti-coagulation at therapeutic level with structural heart disease but 
no recent clinical change 
  
14. Hypertension 
14.1 Indicated 
a. Suspected LV dysfunction 
b. Evaluation of LVH and LV remodelling where this will alter management 
c. Evaluation of clinically suspected aortic coarctation. 
14.2 Not indicated 
a. Routine assessment 
b. Repeat assessment of LV function in asymptomatic patients 
c. Repeat assessment for LV mass regression 
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15. Aortic and Major Arterial Disease 
15.1 Indicated 
a. Suspected aortic dissection: diagnosis, location, extent (TOE) 
b. Assessment of aortic aneurysm and aortic dilatation: diagnosis, location, extent (consider 
TOE) 
c. Suspected aortic rupture and intramural haematoma 
d. Periodic repeat assessment of aortic root and ascending aortic dilatation 
e. Assessment of suspected or proven connective tissue disorder in which aortic pathology 
may be a feature, eg Marfans 
f. Repeat assessment of prior surgical repair of aorta 
15.2 Not indicated 
None relevant 
  
16. Pre-Operative Echocardiography for Elective and Semi-urgent Surgery 
16.1 Indicated 
a. Documented ischaemic heart disease with reduced functional capacity (<4 METS) 
b. Unexplained shortness of breath in the absence of clinical signs of heart failure if ECG 
and/or CXR abnormal 
c. Murmur in the presence of cardiac or respiratory symptoms 
d. Murmur in an asymptomatic individual in whom clinical features or other investigation 
suggest severe structural heart disease. 
16.2 Not indicated 
a. Repeat assessment of previous echocardiogram with no intervening change in clinical 
status 
b. Routine pre-operative echocardiography 
In-Patient Triage  
Appropriate triage categorization is dependent on accurate information being given in the 
request form. It is recognized that failure to provide adequate information may lead to delay. 
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The triage categories are: 
Category 1 (Emergency) 
Echocardiography to be done immediately 
8.1a        Likely acute pericardial tamponade (following interventional procedure including 
intracardiac catheter or pacing manipulation) 
10.1c      Likely acute (massive) pulmonary embolism to inform a decision regarding 
thrombolysis 
Category 2 
Result likely to change immediate patient management and to be done <24 hours. Priority 
within that time to be discussed (may be emergency) 
5.1b        Detection of high-risk complications of infective endocarditis where patient is 
haemodynamically unstable. 
6.1b        Murmur following acute or recent myocardial infarction where papillary muscle 
rupture or ventricular septal rupture suspected. 
7.1d        Persistent hypotension of unknown cause where patient haemodynamically unstable 
and not responding to intensive care. 
8.1a        Suspected pericardial tamponade. 
8.1b        Suspected pericardial effusion or bleeding (including after serious chest trauma). 
15.1a      Suspected aortic dissection (including following possible deceleration injury) 
Category 3 
Echocardiography indicated but may not change immediate management. Echocardiography 
should be done as an in-patient if possible. If resources do not allow this, it may be performed 
as an outpatient but should be discussed with the referring clinicians. 
All other indications for echocardiography. 
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Appendix 2 Scan of signed off Ethics Approval
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Appendix 3 Classification of Iron Overload Syndromes 
Hepatology. 2011 Jul; 54(1): 328–343. doi:  10.1002/hep.24330 
Classification of Iron Overload Syndromes 
Hereditary Hemochromatosis 
 HFE-related 
  C282Y/C282Y 
  C282Y/H63D 
  Other HFE mutations 
 Non–HFE-related 
  Hemojuvelin (HJV) 
  Transferrin receptor-2 (TfR2) 
  Ferroportin (SLC40A1) 
  Hepcidin (HAMP) 
  African iron overload 
Secondary Iron Overload 
 Iron-loading anemias 
  Thalassemia major 
  Sideroblastic 
  Chronic hemolytic anemia 
  Aplastic anemia 
  Pyruvate kinase deficiency 
  Pyridoxine-responsive anemia 
 Parenteral iron overload 
  Red blood cell transfusions 
  Iron–dextran injections 
  Long-term hemodialysis 
 Chronic liver disease 
  Porphyria cutanea tarda 
  Hepatitis C 
  Hepatitis B 
  Alcoholic liver disease 
  Nonalcoholic fatty liver disease 
  Following portocaval shunt 
 Dysmetabolic iron overload syndrome 
Miscellaneous 
 Neonatal iron overload 
 Aceruloplasminemia 
 Congenital atransferrinemia 
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c 
1. Table 2 describes the genetic and clinical features of major clinical syndromes 
related to hereditary hemochromatosis.  Cançado R., Chiattone C., Current 
approach to Hemochromatosis.  Rev. Bras. Hematol. Hemoter.  2010  
vol.32 no.6 São Paulo  
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Appendix 4 Prevalence of the common HFE polymorphisms 
Prevalence of the common HFE polymorphisms C282Y and H63D in the general population.  
Authors  Ref.  
Country – 
Population  
Individuals 
screened  
Allele frequency for  
    
c.845 C > A 
(Y282)  
c.187 C > G 
(D63)  
Beckman et al. 
(1997)  
[ 7]  Mordvinia  85  0.0176  
 
  
Finland  173  0.052  
 
  
Sweden – Saamis  151  0.0199  
 
  
Sweden – Saamis  206  0.0752  
 
Merryweather-
Clarke et al. (1997)  
[ 8]  UK  368  0.060  0.12  
  
Ireland  45  0.1  0.189  
  
Iceland  90  0.067  0.106  
  
Norway  94  0.074  0.112  
  
Former USSR  154  0.010  0.104  
  
Finland  38  0  0.118  
  
Denmark  37  0.095  0.22  
  
Netherlands  39  0.026  0.295  
  
Germany  115  0.039  0.148  
  
Ashkenazi  35  0  0.086  
  
Italy  91  0.005  0.126  
  
Greece  196  0.013  0.135  
  
Turkey  70  0  0.136  
  
Spain  78  0.032  0.263  
Datz et al. (1998)  [ 9]  Austria  271  0.041  0.258  
Burt et al. (1998)  
[ 
10]  
New Zealand of 
European ancestry  
1064  0.070  0.144  
Jouanolle et al. 
(1998)  
[ 
11]  
France – Brittany  1000  0.065  
 
Merryweather-
Clarke et al. (1999)  
[ 
12]  
Scandinavia  837  0.051  0.173  
Distante et al. (1999)  
[ 
13]  
Norway  505  0.078  0.229  
Olynyk et al. (1999)  
[ 
14]  
Australia  3011  0.0757  
 
Marshall et al. 
(1999)  
[ 
15]  
USA – non-
Hispanic whites  
100  0.05  0.24  
Beutler et al. (2000)  [ USA – whites  7620  0.064  0.154002625  
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Authors  Ref.  
Country – 
Population  
Individuals 
screened  
Allele frequency for  
16]  
Steinberg et al. 
(2001)  
[ 
17]  
USA – non-
Hispanic whites  
2016  0.0637  0.153769841  
Andrikovics et al. 
(2001)  
[ 
18]  
Hungarian blood 
donors  
996  0.034  0.014  
Pozzato et al. (2001)  
[ 
19]  
Italy – Celtic 
populations  
149  0.03691  0.144295302  
Byrnes et al. (2001)  
[ 
20]  
Ireland  800  0.1275  0.171875  
Beutler et al. (2002)  
[ 
21]  
USA – non-
Hispanic whites  
30,672  0.0622  
 
Guix et al. (2002)  
[ 
22]  
Spain – Balearic 
Islands  
665  0.0203  0.201503759  
Deugnier et al. 
(2002)  
[ 
23]  
France  9396  0.07636228  
 
Cimburova et al. 
(2002)  
[ 
24]  
Czech Republic  254  0.03937008  0.142  
Van Aken et al. 
(2002)  
[ 
25]  
Netherlands  1213  0.06141797  
 
Phatak et al. (2002)  
[ 
26]  
USA  3227  0.0507  0.1512  
Jones et al. (2002)  
[ 
27]  
UK  159  0.085  0.173  
Candore et al. (2002)  
[ 
28]  
Italy – five regions  578  0.025  0.147  
Salvioni et al. (2003)  
[ 
29]  
Italy – North  606  0.0470297  0.143564356  
Papazoglou et al. 
(2003)  
[ 
30]  
Greece  264  0  0.089015152  
Sanchez et al. (2003)  
[ 
31]  
Spain  5370  0.03156425  0.208007449  
Mariani et al. (2003)  
[ 
32]  
Italy – North  1132  0.032  0.134  
Altes et al. (2004)  
[ 
33]  
Spain – Catalonia  1043  0.0282838  0.19894535  
Adams et al. (2005)  
[ 
34]  
USA – whites  44,082  0.06825915  0.153157751  
Barry et al. (2005)  
[ 
35]  
USA – non-
Hispanic whites  
3532  0.057  0.14  
Meier et al. (2005)  
[ 
36]  
Germany  709  0.044  
 
Matas et al. (2006)  
[ 
37]  
Jewish populations 
– Chuetas  
255  0.00784314  0.123529412  
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Authors  Ref.  
Country – 
Population  
Individuals 
screened  
Allele frequency for  
Hoppe et al. (2006)  
[ 
38]  
USA – non-
Hispanic whites  
991  0.05499495  0.134207871  
Aranda et al. (2007)  
[ 
39]  
Spain – 
Northeastern  
812  0.03140394  0.219211823  
Terzic et al. (2006)  
[ 
40]  
Bosnia and 
Herzegovina  
200  0.0225  0.115  
Floreani et al. (2007)  
[ 
41]  
Italy – Central  502  0.0189243  0.148406375  
Raszeja-
Wyszomirska et al. 
(2008)  
[ 
42]  
Poland – 
Northwestern  
1517  0.04416612  0.154251813  
From this allelic frequency for C282Y, a genotype frequency of 0.38% or 1 in 260 for C282Y 
homozygosity can be calculated from the Hardy–Weinberg equation. The reported frequency 
of C282Y homozygosity is 0.41%, which is significantly higher than the expected frequency. 
This probably reflects a publication or ascertainment bias.  
Significant variations in frequencies of the C282Y allele between different geographic 
regions across Europe have been reported with frequencies ranging from 12.5% in Ireland to 
0% in Southern Europe (Fig. 1).  
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Appendix 5 Prevalence of HH and percentage of study subjects with 
lab Evidence of the disorder 
http://www.aafp.org/afp/2002/0301/p853. html 
Prevalence of C282Y homozygosity and C282Y/H63D compound heterozygosity in 
clinically recognized hemochromatosis. 
 
Authors Ref. 
Study 
population 
Prevalence of HLA/HFE among clinical 
hemochromatosis cases 
   
No. of 
cases 
C282Y 
homozygote 
C282Y/H63D 
compound 
heterozygote 
Wild 
type 
both 
alleles 
Feder et al.,. (1996) [1] 
USA – 
Multicenter 
187 148 
 
21 
Jazwinska et al.,. 
(1996) 
[43] Australia 
112 112 0 
 
Jouanolle et al.,. 
(1996) 
[44] France 
65 65 3 0 
Beutler et al.,. (1996) [45] 
USA – 
European 
origin 
147 121 
  
Borot et al.,. (1997) [46] 
France – 
Toulouse 
94 68 4 18 
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Authors Ref. 
Study 
population 
Prevalence of HLA/HFE among clinical 
hemochromatosis cases 
Carella et al.,. (1997) [47] 
Italy – 
Northern 
75 48 5 
 
Datz et al.,. (1998) [9] Austria 
40 31 
  
Willis et al.,. (1997) [48] 
UK – Eastern 
England 
18 18 
  
The UK 
Haemochromatosis 
Consortium (1997) 
[49] 
UK – 
Consortium 
115 105 
 
5 
Press et al.,. (1998) [50] 
USA – 
Portland 
37 12 
  
Cardoso et al.,. (1998) [51] Sweden 
87 80 3 1 
Sanchez et al.,. (1998) [52] Spain 
31 27 2 1 
Ryan et al.,. (1998) [53] Ireland 
60 56 1 2 
Nielsen et al.,. (1998) [54] 
Germany – 
Northern 
92 87 4 
 
Murphy et al.,. (1998) [55] Ireland 
30 27 
  
Mura et al.,. (1999) [56] 
France – 
Brittany 
711 570 40 35 
Brissot et al.,. (1999) [57] 
France – 
Northwest 
217 209 4 2 
Bacon et al.,. (1999) [58] USA 
66 60 2 
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Authors Ref. 
Study 
population 
Prevalence of HLA/HFE among clinical 
hemochromatosis cases 
Brandhagen et al.,. 
(2000) 
[60] 
USA – Liver 
transplant 
recipients 
5 4 
  
Rivard et al.,. (2000) [60] 
Canada – 
Quebec 
32 14 3 8 
Papanikolaou et al.,. 
(2000) 
[61] Greece 
10 3 
 
5 
Guix et al.,. (2000) [62] 
Spain – 
Balearic 
Islands 
14 13 
  
Brandhagen et al.,. 
(2000) 
[63] USA 
82 70 
 
2 
Sham et al.,. (2000) [64] 
USA – 
Minnesota 
123 74 15 6 
Van Vlierberghe et 
al.,. (2000) 
[65] 
Belgium – 
Flemish 
49 46 2 1 
Bell et al.,. (2000) [66] Norway 
120 92 3 
 
Hellerbrand et al.,. 
(2001) 
[67] 
Germany – 
Southern 
36 26 3 2 
de Juan et al.,. (2001) [68] 
Spain – 
Basque 
population 
35 20 4 2 
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Authors Ref. 
Study 
population 
Prevalence of HLA/HFE among clinical 
hemochromatosis cases 
Guix et al.,. (2002) [22] 
Spain – 
Balearic 
Islands 
30 27 2 0 
De Marco et al.,. 
(2004) 
[69] 
Italy – 
Southern 
46 9 10 11 
Bauduer et al.,. (2005) [70] 
France – 
Basque 
population 
15 8 2 
 
Cukjati et al.,. (2007) [71] Slovenia 
21 10 2 2 
 
 
The authors concluded that (1) future studies to discover modifier genes that affect 
phenotypic expression in C282Y hemochromatosis should help identify patients who are at 
greatest risk of developing iron overload who may benefit from continued monitoring of iron 
status, and (2) although genetic testing is well-accepted and associated with minimal risk of 
discrimination, generalized population screening in a primary care population as performed in 
the HEIRS study is not recommended. 
In a substudy of Caucasian participants in the HEIRS study, Adams et al (2013) assessed the 
prevalence of HFE mutations in patients who had elevated serum ferritin levels less than 
1000 µg/L (300-1000 µg/L for men, 200-1000 µg/L for women).(20) Among 3359 men and 
2416 women, prevalence of potential iron-loading HFE genotypes (defined as C282Y 
homozygote, C282Y/H63D compound heterozygote, or H63D homozygote) was 10% and 
12% in men and women, respectively. Prevalence of C282Y homozygosity was 2% and 4% 
among men and women, respectively. Likelihood of C282Y homozygosity increased with 
increasing serum ferritin levels, from 0.3% to 16% in men, and from 0.3% to 30% in women. 
Posttest likelihood ratios (likelihood of C282Y homozygosity given a positive test result) 
exceeded 1 at serum ferritin levels of 500 µg/L or more for men and at levels greater than 300 
µg/L for women. In Caucasian subjects with mild hyperferritinemia, causes of elevated serum 
ferritin level other than C282Y or H63D HFE mutations (eg, liver disease, diabetes) were 
more likely. 
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Appendix 6 A BSE Guideline Protocol for the Echocardiographic 
assessment of Diastolic Dysfunction   
NEW GUIDELINES 
A Guideline Protocol for the Echocardiographic assessment of 
Diastolic Dysfunction  (Published November 2013) 
 
Echocardiography plays a central role in the non-invasive evaluation of diastole and should be interpreted in the 
clinical context. 
 
Multiple echocardiographic measurements have been proposed to assess diastolic function but no single 
parameter should be used in isolation. This document gives recommendations for the image and analysis dataset 
required for the assessment of diastolic dysfunction (DD) using established indices acquired as part of the 
minimum dataset. Due to the variable sensitivity and specificity of the available parameters in different clinical 
settings, contradictory data can occur and in a proportion of patients a final diagnosis may not be achieved. In 
these situations the conventional echo data should be supplemented with information from other forms of 
assessment including haemodynamic measurement. 
 
In this document, the parameters assessed are first set out systematically, with the key measurements highlighted 
in bold. For ease of reference they are also listed below. A simplified flow chart follows to assist in diastolic 
dysfunction grading.  
 
Appendix 1 summarises normal values. Appendix 2 provides recommendations on assessing diastolic function 
in specific clinical situations. 
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Abbreviations: 
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NOTE: key parameters are highlighted in bold. The remaining parameters are useful adjuncts when the 
diagnosis of diastolic dysfunction severity remains unclear. 
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Appendix 2 
 
In certain clinical situations, conventional echo indices cannot be readily applied to assess diastolic dysfunction. 
The following section provides recommendations on assessing diastolic function in this group of patients. In 
these patients, grading of DD is not always possible and the aim is to estimate the filling pressures as a marker 
of diastolic dysfunction. 
 
a. Left ventricular hypertrophy: In patients with heart failure symptoms and normal EF, evidence of 
concentric remodelling or raised LV mass index is itself indicative of diastolic dysfunction. In this group of 
patients, assessment of other markers of diastolic dysfunction does not provide additional diagnostic 
information  
b. Sinus tachycardia: E A fusion occurs rendering E/A ratio and deceleration time unreliable in assessing DD. 
E/e’ ratio using fused peak mitral inflow velocity and peak fused mitral annular velocity can still be used to 
predict LV filling pressures in this situation. 
c. Atrial Fibrillation: Loss of atrial contraction, variable cycle length and the frequent occurrence of atrial 
dilatation limit the usefulness of conventional indices in the assessment of DD. DT and E/e’ ratio averaged 
over 5-10 cardiac cycles (recorded from cycle lengths equivalent to a heart rate between 60-80 
beats/minute) can be used to assess LV filling pressures in this group. 
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d. Constrictive pericarditis: Constrictive pericarditis can present with heart failure symptoms and restrictive 
filling pattern (Grade III) in the absence of diastolic dysfunction. Normal or increased e’ velocity can 
differentiate this condition from DD. 
e. Mitral valve disease: Mitral E Vmax and PVs are affected by significant primary MR. a dur- A dur is the 
strongest predictor of LV filling pressure in this situation. 
f. Systolic dysfunction: Grading of DD and estimation of filling pressures provide additional prognostic 
information in patients with established systolic dysfunction. Mitral inflow pattern (E/A ratio and DT) alone 
can be used to estimate filling pressure in this population and no further evaluation is necessary except in 
borderline cases. Accordingly E/A ratio < 1 in this population often indicates normal filling pressures and 
E/A ratio of 1-2 or > 2 strongly suggest raised pressures. 
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Appendix 7  Mitral Inflow Pulsed Wave Doppler Profiles 
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Appendix 8  A practical Approach to the assessment and grading of 
Diastolic Dysfunction 
 
 
 
 
